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SU M M A R Y
Ovarian cancer arises almost exclusively in epithelial cells derived from the surface 
of the ovary. It is thought that the continual damage caused by ovulation (break of 
the epithelial surface layer to allow release of tire follicle) and the subsequent repairs 
aie the prime factors in promoting ovarian epithelial cancer. The prime promoter of 
growth repair is epidermal growth factor (EGF). EGF works through the EGF 
receptor (EGFr) and EGFr has been detected in about 45% of ovairan cancer. 
Epidermal growth factor and transforming growth factor alpha are tw o peptides 
which bind to the epidermal growth factor receptor. Although the literature shows 
that epidermal growth factor (EGF) was detected in less than 30% of ovarian
cancers, transforming growth factor alpha (TG Fa) was present in 88.5%. To
investigate the possible role of growth factors in ovarian carcinoma, the OAW42 
epithelial ovarian cancer cell line (previously established from ascites of patient with 
ovarian cancer) was used as a model. To allow these studies to be extended to the 
effects o f drug resistance, P E O l and PEO lcddp cells were used (PEO l was a 
platinum sensitive cell line, PEOlcddp a platinum resistant cell line).
Growth stimulation of OAW 42 cells over 48 and 72 hours by T G F a reached a
maximum of 42 and 19.6% above control respectively at 10 ng/ml dose.
Growth stim ulation by T G F a was seen in PE O l cells as early as 24 hours,
reaching a maximum of 35% above control at 25 ng/ml.
Growth response to EGF showed that OAW42 cells responded positively to the 
influence of EGF after 48 and 72 hours reaching a maximum of 34% above control 
at 10 ng/ml. PE O l cells again showed earlier stimulation o f growth by EGF 
reaching a maximum of 18.9% after 24 hours, 30.8% at 48 hours, and 16.1% after 
72 hours at dose of EGF (2.5 ng/ml). Both cell lines were, EGFr positive, as 
expected. After 24 hours exposure of PEO lcddp cells to EGF, a slight stimulation 
o f growth was seen at a dose of 5 ng/ml (about 6.3% above control). After 48 
hours no stimulation of cell proliferation seen. At 72 hours exposure PEO lcddp 
cell growth was inhibited by all concentrations of EGF, suggesting that acquision 
of drug resistance was also associated with changed response to EGF.
XV
TGFp, a known inhibitor of the proliferation of normal ovaiian epithelial cells was
shown to inhibit growth of OAW42 cells over 96 hours reaching a maximum of 
35% at 5 ng/ml. After treating OAW 42 cells with luteinzing hormone (LH), cells 
showed inhibition of growth reaching a maximum of 21, 26.2, and 30.1% after 24, 
48, and 72 hours respectively at 60 iu/1 dose of LH. PEO l cells showed growth 
inhibition, reaching a maximum of 34.2, 26.9, and 32.8% below control after 24,
48, and 72 hours respectively at 60 iu/1 dose o f LH. Anti-TGFP polyclonal 
antibody (5 fil/ml) reversed LH-induced inhibition of growth. A further increase of 
an ti-T G F p  antibody up to 30 |Lil/ml gave growth stimulation of 11.3% above
control cells suggesting that TGFp is normally having some inhibitory effects on
the cells under control conditions in addition to mediating the LH response.
Cancer and other hyperproliferative diseases often show elevated protein tyrosine 
kinase (PTK) activity, related to the increased activity of growth factor receptors. 
In the present study, there was growth inhibition of OAW42 cells over 72 hours by 
blocking PTK with an EGF receptor specific tyrosine kinase inhibitor, reaching a
m axim um  of 38.3% below control cell giowth at 3.0 |iM  dose. PEO l and
PEO lcddp cells were also growth inhibited by increasing concentrations of TKI
from (0.5 to 3.0 jlM) reaching a maximum of 55.0 and 59.3% below control
respectively at 3.0 |iM  dose. This confirmed the importance of EGF as a growth 
promoter in at least some ovarian cancers.
Electron microscopy was used to study the hormonaly-induced changes in the 
cellular morphology o f ovarian cancer cells. The actions of LH were compared 
with those of epidermal growth factor (EGF). Exposure of OAW42 cells to EGF at 
10 ng/ml dose for up to 72 hours showed swollen mitochondria, more evidence of 
polysomes and more stubby microvilli, in keeping with the growth response to 
EGF seen after 72 hours incubation. The effect o f LH showed no evidence of 
swollen mitochondria, no prominent polysomes and few stubby microvilli, this 
time reflecting the growth inhibition of higher doses of LH.
XVI
On the basis of the results described in this thesis, new therapies for ovarian cancer 
may be based on either regulation of the EGF receptor or promotion of the action of
TG Fp.
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C H A PT E R
IN T R O D U C T IO N
1.1 An Introduction to Cancer
About 140 years ago a German microscopist, Johannes Mueller, showed that 
cancers were made up of cells, a discovery which began the search for changes 
which would help to pinpoint the specific differences between normal and cancer 
cells. The visible tumour is the end result of a whole series of changes and may 
have taken many years to develop. Cancer is not a single disease but many diseases 
sharing a single name. It is the spread of malignant tumours, particularly to vital 
organs, that makes them both difficult to treat and potentially lethal.
Tumours can be either malignant or benign. Those that remain localised can usually 
be cured by surgery or radiotherapy e.g patients with large basal cell skin cancer 
can be treated successfully as these tumours rarely invade deep into the skin or 
spread to lymph nodes.
Some tumours, especially deep-seated ones, can become quite large (up to 1-2 cm 
diameter) with no symptoms being noticed during a routine medical examination. 
M alignant tumours escape norm al biological controls and, further, support 
themselves on nutrients which were intended for healthy cells or organs. Malignant 
tumours will initially invade and destroy the surrounding tissue, then enter both the 
lymphatic supply and the blood stream.
1.2 Spread of Cancer
Spread o f cancer cells (metastatic cells) may occur via the blood stream or the 
lymphatic channels or across body cavities such as the pleural and peritoneal 
spaces setting up secondary tumours (see figure 1), causing different effects in 
different part of the body e.g a lung tumour may invade the chest wall causing pain 
on breathing due to pleural irritation. Bone metastasis is very common in breast 
cancer but very rare in cancer of the ovary, which presumably reflects the fact that 
metastatic cells are seeking a growth environment similar to that present in the 
parent tissue.
Figure 1. The spread of malignant tumours.
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1.3 Some F ac to rs  R elated  to  C arcinogenesis
Many different factors are involved in the development o f tumours: a cancer 
producing agent (carcinogen) and presumably promoting agents must be present, 
though not necessarily at the same time. These factors may be chemical or 
physical. For example, ultraviolet light can cause skin cancer in Caucasians 
exposed to tropical sun light. Identified chemical carcinogens include hydrocaiton 
carcinogens present in coal and tar and a series of chemicals used in the rubber 
industry, such as 2 naphthylamine, benzidine and 3-dichloro benzidine. Cigarette 
smoke remains the most common source of carcinogen. Alcohol consumption can 
cause cancer of the oesophagus and larynx.
Animal experiments suggest that viruses may be associated with the initiation of 
some cancers e.g the leukaemic virus group. Viruses also seem to be associated 
with some types of human cancer e.g. cervical cancer (HPV 16 and 18). Some 
tum ours (e.g. a rare m alignant tum our o f the retina occum ng  in infant- 
retinoblastoma) are inherited through gene deletion in the parental DNA. Other 
cancer families inherit mutations in certain genes e.g. the BRCA-1 tumour 
suppressor gene on chromosome 17q was identified and shown to be responsible 
for some cases of hereditary breast/ovarian cancer families (Berchuck et al 1995). 
It has been estimated that women who carry mutations to the BRCAl gene on 
chromosome 17q have 60% lifetime risk of ovarian cancer. A series families with 
either breast or ovarian cancer, identified 40% with BRCAl mutations (Simard et at 
1994).
1.4 In tro d u c tio n  to the O vary  and  to O varian  C ancer
There are two ovaries situated in the lower abdomen, one on each side of the 
uterus. Each ovary contains numerous follicles within which the ova develop (see 
figure 2). Normally, there is only one mature follicle in the ovary prior to 
ovulation. The ripening follicle contains a large fluid cavity that distends the 
surface of the ovary.
Figure 2. The mature mammalian ovary
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Diagram of a mammalian ovary, showing the sequential development of a follicle, 
formation of a corpus luteum, and in the centre,follicular atresia. A section of the 
wall of a mature follicular is enlarged at the upper right. The interstitial cell mass is 
not prominent in primates. [Adapted from Katzung BG Basic and Clinical 
Pharmacology, 1987].
The follicle secretes oestrogen and small amounts of androgen. After ovulation a 
corpus luteum forms at the site of the ruptured follicle and secretes progesterone. 
Oestrogen and progesterone regulate the changes in the uterus throughout the 
menstrual cycle and pregnancy. A repair mechanism stimulates growth of the 
surface epithelium in the area of the damage caused by ovulation.
1.4.1 Functions of The Ovary
The ovary has two main functions in the body, (a) the gametogenic function of 
production of the female germinal cells, (b) an endocrine function, consisting of 
the elaboration of female hormones (oestrogens, progesterone and relaxin) and 
some androgens. Both functions are performed, to a large extent, by the same 
ovarian cells. The maturation of germinal cells occurs in the evolving follicles. The 
elaboration of oestrogens is accomplished by the theca interna layer, with the final 
step (aromatisation) taking place in the granulosa cells of evoluting and involuting 
follicles and by the theca lutein cells of corpora lutea. Progesterone is produced by 
the granulosa lutein cells of the corpora lutea, which also produce relaxin ; the hilus 
cells and theca cells produce androgens.
1.4.2 The Effect of LH and FSH on the Normal Ovary
The processes of differentiation, function and degeneration in the cells of the ovary 
appear to be under the influence of secretion of the pituitary gonadotrophins, 
follicle-stimulating hormone (FSH) and luteinizing hormone (LH) (Findlay and 
Risbridger 1987).
The ovary and testis share homology of structure and function in the production of 
gametes and in the regulation o f steroidogenesis. Normal function of both the 
ovary and the testis is dependent on the pituitary-synthesized gonadotrophins
(Ronin et al 1989). These are glycoprotein dimers, which share a common a -  
subunit. Follicular maturation is also under the control of these gonadotrophins.
These glycoproteins act through their receptors on their target cells, indicating the 
presence of functional gonadotrophin receptors at an early stage of follicular 
development (Asem et al 1992). FSH also regulates granulosa cell function during 
the follicular phase of development (Cahill et al 1985; Carson et al 1988).
The LH surge that promotes ovulation involves local release o f prostaglandins, 
together with FSH and LH induced release of plasminogen which mediates the 
release of the oocyte from the follicle wall (Beers et al 1985).
1.4.3 Normal Pituitary and Ovarian Relationships
During the normal ovarian cycle, oestrogen secretion down-regulates FSH and LH. 
After the menopause feedback inhibition on pituitary peptide hormone synthesis is 
lost such that the pituitary produces increased amounts o f follicle stimulating 
hormone (FSH) and luteinizing hormone (LH) (5-15-fold above normal pre­
menopausal levels) for a number of years after the climacteric (Monroe et al 1977). 
This suggests that FSH and LH may contribute to the development of ovarian 
cancer as the m ajority o f ovarian cancer patients are post-m enopause. 
Nevertheless, the marked changes in relative risk o f ovarian cancer in relation to age 
at menopause might suggest that the initial events in ovarian carcinogenesis occur 
before the menopause. The ovary secretes a variety of steroid hormones, though
only oestradiol-17|3 and progesterone are known to have established feedback roles
in controlling the secretion of pituittury gonadotiophins, see (figure 3). Oestradiol-
17p, which is formed within the ovarian follicle, has been shown to have direct
actions on follicular cells such as influencing the activities of various steroidogenic 
enzymes (Findlay and Risbridger 1987). In both phases of the ovarian cycle it is 
the principal steroid inhibiting the release o f gonadotrophins (LH and FSH) from 
the anterior pituitary (negative feedback). Oestradiol in the female will also provoke 
a discharge or surge of LH (positive feedback) at mid-cycle (Diersehke et al 1974).
Figure 3. Hormonal control of ovarian function
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The pituitary gland produces gonadotrophin hormones LH and FSH which act to 
stimulate the ovary to produce oestrogen and progestrone, which then act on target 
tissues to induse a response. In addition, oestrogen is capable of controlling release 
the gonadotrophin hormones by feed back inhibition.
A failure of positive feedback to the hypothalamus at mid-cycle will result in a 
failure of ovulation and accounts for the occurrence of anovulatory cycles in the few 
months after the menarche in rhesus monkeys and in adolescent girls (Diersehke et 
al 1974).
Progesterone has little effect on the release of gonadotrophins but inhibits the ability 
o f oestrogen to provoke positive feedback (Diersehke et al 1973).
O varian androgens (mainly androstenedione) may influence the release of 
gonadotrophins, either directly, or by extra-glandular aromatization to oestrogens 
(Martenz ef £z/ 1975).
1.5 Epidemiology of Ovarian Cancer in the West and in Libya
The highest ovarian cancer rates are reported in highly industrialised countries, 
except Japan where rates of death from ovarian cancer are the lowest in the world 
(Bull et al 1965,1968). Japanese migrants to USA and their first-generation 
offspring in the United States have a higher incidence o f ovarian cancer than 
Japanese women in Japan, although the incidence is still lower than that in the white 
women of the United States. Ovarian cancer rarely occurs before menarche and is 
unusual before age 20, but the rate of occunence tends to increase significantly 
thereafter. In the age range 40-44, the incidence is 15.7 per 100,000 women, while 
the incidence increases to 54 per 100,000 women in the 75 to 79 age group. 
Disordered endocrine function may contribute to the development of ovarian cancer. 
A higher incidence of epithelial tumours has been noted in women with a lower 
mean number of pregnancies, in nulliparous women, and in women with a history 
of infertility (Jely et al 1974). Repeated trauma to the surface of the epithelium 
during normal ovulation increases ovarian cancer risk (Fathalla 1971). High 
circulating levels of pituitary gonadotrophins are thought to be active in ovarian 
cancer development and the reduction in plasma gonadotrophin levels in oral 
contraceptive users is assumed to be responsible for the decrease in the risk of 
ovarian cancer in pill users though reduction in the numbers of subsequent wound 
repairs is a more likely explanation (Cramer et al 1983).
An increasing risk of ovarian cancer is associated with nulliparity, non-use of oral 
contraceptive, and increasing ovulatory years (Whittemore 1993).
The relative risk of ovarian cancer is 1.0 for women who reach menopause before 
age 45, after which it rises rapidly to 4.5 for women whose menopause is 55 years 
or later suggesting some increase in cai'cinogen secretion from older ovaries.
The risk of ovarian cancer decreases with each additional pregnancy (Kvale eta l 
1988) and (Hartge et al 1989). Most studies have noted a decreased risk among 
women who breast feed (Hartge et al 1989) and (Gwinn et al 1990). Oral 
contraceptive use, particularly for 5 years or more, has also been consistently 
found to result in reduction in risk (Hankinson et al 1992). There is a small 
decrease in ovarian cancer risk with even lyear o f oral contraceptive use, but 
longer durations of use are needed for a substantial risk reduction (Susan e ta l  
1992). Both nulliparous and parous women who use oral contraceptive have a 
decreased risk of ovarian cancer. The incidence of epithelial ovarian cancer is 
reduced by approximately 30% in oral contraceptives users. However the risk of 
ovarian cancer is associated with a 50% reduction in long-term users over five years 
of use (Vessey and Painter, 1995) and 70% in those taking oral contraceptive for 
more than 97 months.
Unprotected intercourse and/or prior use of infertility medication increased risk of 
invasive ovarian cancer, although age at first live birth, age at menarche, age at 
menopause, and oestrogen replacement use were not strongly associated with risk, 
while pregnancy, breast feeding, and oral contraceptive use are associated with risk 
reduction. An underlying hormonal imbalance might be responsible for infertility 
and, rather than ovulatory activity, may be responsible for the increased incidence 
o f ovarian cancer observed in nulliparous women (W hittemore et al 1989). 
W omen who have had one to two pregnancies have a risk of 0.49 to 0.97 and 
women with three or more pregnancies have a relative risk of 0.35 to 0.76. Each 
additional pregnancy appears to lower the risk by about 10% (Greene et al 1984). 
Cancer of the ovary and breast appear to share some common etiologic factors. 
Women with breast cancer have twice the expected risk for ovarian carcinoma, 
women with ovarian cancer have a three-fold to four-fold increase in the incidence 
of breast cancer (Fraumeni et al 1974).
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Epithelial ovarian cancer accounts for about 90 percent of all malignant ovarian 
tumours (Berek et al 1989). This form of ovarian cancer often spreads without 
symptoms, and in three quarters of patients the disease is not diagnosed until it has 
spread beyond the pelvis. Approximately 70% of patients present with advanced 
stage disease at diagnosis and 85% of them eventually die as a result o f their 
disease (Richardson et al 1985).
Ovarian cancer is the fourth commonest cause of cancer death in women and the 
leading cause of gynecologic cancer death in the United States (Silverberg 1983). 
More U.S. women die from ovarian cancer each year than from cervical and 
endom etrial carcinom a com bined (Boring et al 1992). U.S. incidence and 
mortality estimates for 1992 indicate that 21,000 new patients are diagnosed yeaiiy 
and 13,000 women die from this disease. In the UK there are 4,000 new cases 
diagnosed every year. Overall five-year survival rate is 28% and there are 3,000 
deaths each year. In contrast to western women, malignant tumour of cervix is the 
commonest malignant tumour of the genital tract of the Libyan women (Table 1). 
The reasons for higher frequency of carcinoma of cervix in Libyan women may be 
attributed to early marriage, multiparity and lack of screening. The most common 
ovarian neoplasms in Libyan women were the germ cell tumours (51.1 and 47.7% 
in Tripoli and Benghazi respectively (Table 2) (Faizuddin et al 1989) in sharp 
contrast to that in Western women in whom germ cell tumours represent only 2% to 
3% of total ovarian cancers (Woodmff et al 1968).
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Table I. Prevalence of tumours of female genital tract in Tripoli and Benghazi
Tripoli
Site of tumour Number Benign Malignant
Ovary 176 (37.9%) 143 (81.7%) 33 (18.7%)
Uterus 213 (45.9%) 186 (87.3%) 27 (12.3%)
Cervix 66 (14.8%) 2(3.1% ) 64 (96.9%)
Vulva 9 (1.94%) 0 9 (100%)
Total 464 331 (71.3%) 133 (28.66%)
B enghazi
Site of tumour Number Benign Malignant
Ovary 132 (24.4%) 93 (70.5%) 39 (29.5%)
Uterus 320 (59.2%) 272 (85%) 48 (15%)
Cervix 70 (12.9%) 24 (34.3%) 46 (65.7%)
Vulva 19 (3.5%) 0 19 (100%)
Total 541 389 (71.9%) 152(28.1<%)
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Table IL Epithelial and Germ cell tumours in Tripoli and Benghazi.
Tripoli Benghazi
Epithelial tumours 62 (35.3%) 48 (36.36%)
1. Serous and mucinous 55 (31.25%) 46 (34.84%)
Benign (adenoma) 46 (26.14%) 34 (25.75%)
Malignant (carcinoma) 9 (5.%0 12 (9.08%)
2. Brenner 2(1.14% ) -
3. Undifferentiated 3 (1.7%) -
4. Cystadenofibroma 2(1.14% ) 2(1.15% )
Germ cell tumours 90 (51.14%) 63 (47.7%)
1. Benign cystic teratoma 82 (46.6%) 52(39.39%)
2. Malignant teratoma 2(1.14% ) 4(3% )
3. Cystic teratoma with malignant
change - 4 (3% )
4. Dysgerminoma 6 (3.4%) 3 (2.27%)
Total number of tumours 176 132
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1.6 The Biology of O varian Cancer
At the time of ovulation, ovarian surface epithelial cells produce lai'ge lysosomal 
bodies that migrate to the basal region of the cells. These large bodies are excreted 
from the basal surfaces o f the cells before ovulation. It is believed the lysosomal 
bodies contain enzymes that participate in the breakdown of the tunica albuginea 
and thus aid in follicular rupture (Bjersing et al 1975).
The process of ovulation results in a wound at the ovarian surface that is repaired 
by rapid growth of ovarian surface epithelial cells (Nicosia et al 1991). This 
repair process is thought to be stimulated by epidermal growth factor (EOF).
There is also potential for various hormones and other growth factors to regulate 
growth and function o f ovarian surface epithelial cells, as suggested by the 
presence of appropriate receptors for many of these regulatory substances in both 
the normal and malignant ovarian surface epithelial cells (Berchuck e ta l 1991) and 
(Bauknechter al 1988).
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1.6.1 H ereditary O varian C ancer
The present limited data suggested that the life-time risk to a sister or mother of a 
patient in a family, where two or more close relatives are affected, is about 40% 
and that roughly half this risk occurs before the age of 50. This is explained on the 
basis that there is a 50% chance of inheriting the gene and 80% chance that a gene 
carrier will develop ovarian cancer in her lifetime. The risk of developing ovarian 
cancer with one first-degree and one second-degree relative or two second degree 
relatives is less than 50% (Piver et al 1990; 1991).
The biology of familial ovarian cancer is very poorly understood. Between 5% and 
10% of all ovarian carcinomas are hereditary (Lynch et al 1987) and (Schild, Kraut 
and Thompson 1988). Some hereditary ovarian cancer involves only segiegation 
o f ovarian cancer but others show additional forms of cancer, such as carcinoma of 
the breast in the breast/ovarian cancer syndrome.
W omen with a family history of breast, uterine or ovarian cancer in a mother or 
sister showed a highly significant increased risk of ovarian cancer (Mori et al 
1988). The association o f ovarian cancer with breast cancer in families suggests 
that genetic variation in the m etabolism of the steroid hormones could be an 
important factor in giving rise to inherited susceptibility to both cancers. Relative 
risks o f 3.6 for first-degree relatives and 2.9 for second-degree relatives were 
reported (Koch et al 1989).
There are three types of hereditary ovarian cancers: site specific ovarian cancer, 
breast-ovarian cancer syndromes and Lynch II syndrome, which is a combination 
of lynch I hereditary colon cancer and the frequent occurrence of ovarian, breast 
and uterine cancer (Lynch et al 1985 and Lynch et al 1986). Early detection of the 
risk of ovarian cancer will depend on finding the abnormal gene (Narod et al
1991). Narod and colleagues investigated five large families with a predisposition 
to cancer of the breast and ovat’y. BRCA l gene has focused attention as one of the 
genes responsible for some cases of inherited breast and ovarian cancer (Miki et al 
1994). It is estimated that 80% of families with the breast-ovarian syndrome were 
due to the BRCAl locus (Feunteun et al 1993, Easton et al 1993).
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1.6.2 Early Detection of O varian Cancer
Ovarian cancer is a disease that remains without a reliable screening technique for 
early diagnosis. Early detection of epithelial ovarian cancer generally still relies on 
the finding of a pelvic mass on physical exam ination (Jacobs et al 1990). 
Screening techniques using ultrasonography and the serum tumour marker CA 125, 
although widely available, have not greatly enhanced our ability to discover such 
cancers before their dissemination. CA 125 is a 200-kD glycoprotein found as a 
surface protein on ovarian cancer cells (Davis et al 1986) and (Bast et al 1983). 
The monoclonal antibody used in the assay was raised against the antigen OVCA 
433 prepared from a cell line o f a papillary serious cystadenocarcinoma of the 
ovary. CA 125 has been used as a marker to monitor the response of ovarian 
cancer to treatment as well as to distinguish malignant from benign pelvic masses 
(Bast et al 1983) and (Jacobs et al 1989).
The use o f serum levels of CA 125 com bined with vaginal and or abdominal 
sonography, as a screening test for ovarian cancer, remains controversial because 
of a significant number of false positives. In general, monoclonal antibody assays 
developed so far lack sufficient sensitivity and specificity for reliable early 
diagnosis of ovarian cancer (Runowicz et al 1992).
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1.7 T reatm ent of O varian C ancer
Early ovarian cancer is almost always clinically silent and so normally presents 
at an advanced stage with intraperitoneal metastasis. Treatment of advanced stage 
disease has been almost wholly ineffective due to the frequent development of 
resistance to available chemotherapeutic regimens. Taxol is cuirently registered for 
use in ovarian cancer after failure of previous chemotherapy including platinum 
compounds (McGuire, et al 1989, Sarosy, et al 1992).
1.7.1 S urgery
Surgery will continue to play an integral role in the management of malignancy 
including ovarian cancer. It is plays an im portant role in both the staging 
procedure and in the removal of as much tumour as possible (Alders et al 1993). 
It can be helpful in selecting patients for more extended treatment and saving others 
from unnecessary over treatment. Currently, the extent of residual disease, after 
surgery is completed, is the best available index of prognosis (greater than 2cm 
residual disease = poor prognosis).
1.7.2 Prophylactic Oophorectomy
Prophylactic oophorectomy has some times been recommended to women with a 
strong family history of ovarian cancer and others have suggested performing such 
an operation in women over 45 years who are undergoing a hysterectomy for some 
other reason. Lewis and Davison (1969) described a family of five sisters and their 
mother, all with ovarian carcinoma. Prophylactic oophorectomy was performed on 
five women from the next generation. None of these individuals showed histologic 
findings consistent with ovarian carcinoma.
The risk of ovarian cancer in women from families with hereditary ovarian cancer 
syndromes is sufficiently high to warrant prophylactic oophorectomy (Kerlikowske 
e ta l  1992).
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The ovary is the major source of oestrogen in women, (see figure 4). Oestrogen 
receptors have been detected in both nomial and malignant ovarian surface epithelial 
cells (Nicosia, e ra / 1991) and (Hamilton e ra / 1992). The complexity of ovarian 
surface epithelial cell regulation is indicated by the finding of oestrogen production 
by ovarian cancer cell lines (Wimalasena, et al 1982, Poels, et al 1989).
Oestrogen replacement therapy has not been associated with increased risk for 
ovarian cancer (Hoover, et al 1977, Adam, et al 1989).
Presence of functional oestrogen receptors is associated with improved prognosis in 
ovarian cancer patients (Harding et al 1990)
After oophorectomy, women will generally require oestiogen replacement therapy. 
Oestrogen therapy is associated with a decreased risk for fractures (Naessen eta l
1990) and a decreased risk for coronary heart disease (Stampfer et al 1991). 
However, it is important to consider how this oestrogen replacement therapy might 
influence risk of breast cancer.
1.7.3 Tubal Ligation and Hysterectomy
Tubal ligation and hysterectomy were associated with reduced risk (Alice et al
1992). Tubal ligation and hysterectomy may protect against ovarian cancer by both 
impairing ovarian function and by preventing ovarian exposure to exogenous 
carcinogenic agents (such as asbestos talc) that enter the peritoneal cavity through 
the vagina (Whittemone et al 1992).
1.7.4 Chemotherapy
The treatment of patients with ovarian cancer has previously varied enormously 
depending on the clinician’s knowledge and use of various chemotherapeutic drugs, 
either as single agents or multiple agents and his relationship with mainly a medical 
oncologist and less frequently a radiotherapist. The most effective drugs are Cis- 
platinum and carboplatin used, either alone, or in combination with other drugs.
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Figure 4. Oestrogen synthesis
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Cisplatin and carboplatin are the mainstays of therapy in the management of 
advanced-stage epithelial ovarian carcinoma (Muggia et al 1989 and Reed et al
1990). Six pulses o f chem otherapy are usually given one month apart and 
response is observed by monitoring CA-125 levels and through pelvic/abdominal 
assessm ent. Chemotherapy for advanced ovarian cancer with combinations of 
drugs that contain cisplatin appears to yield a substantial proportion of long-term 
survivors (Neijt e ta l  1987). Use of Taxol has recently given good responses in 
platinum -resistant patient. Over the past 15-20 years, the overall mortality for 
ovarian cancer has improved, particularly for younger patients (Hole et al 1991).
1.8 Growth Factors and Ovarian Cancer
1.8.1 Growth Factors Activities in normal and malignant 
epithelia.
The action of hormones is mediated, at least in part, by the regulation of local 
growth control mechanisms. These may be autocrine and/or paracrine in their mode 
of action see (figure 5). Experimental evidence suggests that growth factors play 
extensive roles in the growth o f ovarian epithelial cells following the injuries 
caused by ovulation. If there is a transformed cell in the area of the injury repair, 
then may be the onset of ovarian cancer promotion.
1.8.2 Epidermal Growth Factor
Epiderm al growth factor (EGF) is a 53 amino acid polypeptide with molecular 
weight of approximately 6,000. T G F -a  shows significant homology with EGF 
(Burgess 1989). Both appear to exert their biological effects by binding to high 
affinity EGF-receptors. EGF and/or T G F -a  are present within most ovarian 
tumours (Bauknecht et al 1989 ; Leake et al 1990).
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Figure 5 . Synthesis and delivery of growth factors
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In post pubertal sheep, a depilatory dose o f EGF (4.2pg/kg/hour) for 48 hours
decreased LH and oestradiol (Show et al 1985). A similar EGF infusion inhibited 
ovulation and low ered oestrogen concentrations in pregnant mares serum 
gondotrophin (PM SG )-treated ewes. Subsequent non stim ulated cycles were 
apparently noimal (Bedford etal 1987). These observation confirm that EGF 
action is not simply a local stimulation of mitosis.
EGF has been shown to be a potent mitogen for a variety of cells including rodent, 
porcine and human granulosa cells (Takeshi et al 1993).
In addition to its mitogenic property, it is evident that EGF regulates a variety of 
cellular functions. There is simultaneous expression o f EGF and EGF receptor, not 
only in the granulosa and thecal cells, but also in the stromal cells surrounding the 
corpus albicans. It is highly possible that an autocrine control system wherein 
EGF serves as the signal may exist throughout the life of the ovarian follicle.
EGF has been shown to stimulate the in vitro growth o f malignant ovarian 
tumours specimens (Singletary et al 1987). Normal human ovarian epithelial cells 
express high-affinity epidermal growth factor receptors and epidermal growth 
factor consistently acts to stimulate DNA synthesis in these cells (Rodriguez et al
1991). Ovarian epithelial cells in vivo are quiescent cells that coat the ovarian 
surface at ovulation unless there is a growth stimulus such as that at the time o f 
wound repair.
Follicular cells secrete epidermal growth factor, which then acts in a paracrine 
fashion to stimulate growth of epithelium after rupture of the follicle (Skinner et al 
1987). EG F inhibits FSH -induced LH receptor expression and oestrogen 
production , but stim ulates FSH  recep tor expression and FSH -induced  
progesterone production (Hiramatsu a / 1992), (Mondschein ef a/ 1980, May 
e ta l  1987).
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1.8.3 E G F R  E xpression  In N orm al O varian  E p ithe lu im  
and Ovarian Cancer
Human ovarian epithelial cells normally express EGF-r and EGF may act to 
stimulate regrowth of epithelial cells after disruption of the ovarian surface at 
ovulation (Rodriguez etal 1991). This process could lead to the promotion of any 
transformed epithelial cells leading, eventually, to viable tumour formation.
The presence o f EGF-r has often been detected in tissues derived from ovarian 
carcinomas (Bauknecht e ta l 1989, Kohler et al 1989). The EGF-r was present 
in 39.7% of samples ranging from 36.4% in those tumours which were classified 
as being mucinous to 47.7% in the undifferentiated group (Owens et al 1991). In 
the Bauknecht study EGF-receptor positive carcinomas were associated with a 
better survival rate of the patients. This may have been due to better msponse to 
chemotherapy in the EGFr+v patients. Noimal ovarian epithelial cells express EGF
receptor (10^-10^ receptors per cell) and EGF acts to stimulate proliferation of
these cells (2-5 fold) (Rodriguez et al 1991). Ovarian cancer cell lines were found 
to express similar numbers of high-affinity EGF-receptors, but most of these cell 
lines were relatively resistant to the growth-stimulatory effect o f EGF (Rodriguez 
e ta l  1991) and (Berchucker a/ 1990).
1.8.4 E p id e rm al G row th  F ac to r R ecep to r T yrosine K inase
Epidermal growth factor receptor (EGFr) is a 170 kD transmembrane glycoprotein 
that consists of an extra cellular domain that binds to EGF (Ullrich et al 1990). 
EGF binding activity of receptor preparations was shown to be associated with a 
protein kinase activity. Subsequent studies demonstrated that the EGF binding 
activity and kinase activity were properties of one and the same protein and that the 
kinase activity was a tyrosine phosphorylation (Cohen et al 1980).
In the absence of EGF the apparent tyrosine kinase activity is low. Binding of 
EGF to the receptor domain (figure 6) results in receptor dimerization and
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Figure 6. Dimerization and activation of EGF receptor
/  ■Ligand (EGF) ,1m
Extracellular^ 
domain 
Exterior
Ligand-binding 
B /  site (EGF receptor) 
1  n  LIgand
Autophosphorylation
Recep 
dimerization
on tyrosines
Transmerrtprane
Cytosol
Kinase 
catalytic 
site >Cytosolicdomain
-(P )
11;-(P)
Phosphtyrosir les
(— SH2 domain —
SH2 domain-containing protein
tyrosine kinases is induced by ligand binding. EGF receptor contains an 
extracellular ligand-binding domain, a single transmembrane chain, which is an a - 
helix, and a cytosolic domain with tyrosine kinase activity. An activated receptor 
autophosphoiylates specific tyrosine residues in the cytosolic domain. The resulting 
phosphotyrosines function as binding sites for various proteins containing SH2 
domains. [Adapted from G. Panayotou and W. D. Waterfield. Bioassays 15: 171.
1993].
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subsequent autophosphorylation of the cytoplasmic domain of EGFr at specific 
tyrosine residues (Downward et al 1984). This autophosphorylation results in an 
activation of the tyrosine kinase activity of the EGFr and can initiate the 
physiological effects o f EGF by activating a variety of molecules such as
phospholipase Cy, phosphotidyl inositol 3 kinase and ras GTPa^^ activating
protein (Margolis ef a/ 1992, Ullrich e ra / 1990). Thus, over expression of EGFr 
and/or its ligands can result in rapid promotion of mansformed cells when the 
receptor is functional. The evidence in favour of a role for EGFr is accumulating 
for a wide variety of epithelial cancers. Binding of protein tyrosine kinases occurs 
at highly specific phosphotyrosine residues of the receptor and is believed to be a 
mechanism for signal transduction from the receptor to the final intracellular 
target, including signal transduction to the nucleus (Lia et al 1994) see (figure 7). 
Enhanced RPTK activity resulting from tyrosine kinase over expression or 
amplification following persistent stimulation by autocrine secreted growth factors, 
can lead to disease (Bishop 1987). The activity o f tyrosine kinase has been 
implicated in many cancers and non malignant proliferative diseases (Ross 1993). 
Removal of phosphate groups from phosphorylated tyrosine residues by protein 
tyrosine phosphatases (PTPs) can down regulate the growth stimulatory activity of 
these signalling pathways (Wiener et al 1993). Dephosphorylation by tyrosine 
phosphatases class IB which can block the ability of activated HER-2/«ea to 
transform 3T3 cells (Brown-Shimer 1992).
Normal ovarian epithelium  expresses very little of these phosphatases, but a 
majority of ovarian cancers express variable amounts of it (Wiener 1993).
The exU'a cellular domain of tyrosine kinase growth factor receptors can also be 
used as a target for treatment with monoclonal antibodies, either conjugated with 
toxins or unconjugated. Recent results with immunotoxins directed against C-erb 
B-2 are o f particular interest in that only cells that over express the receptor are
killed by the toxin (Rodriguez 1993).
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Figure 7. Cell signalling pathways and MAP Kinases translocation to the nucleus
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1.8.5 T ran sfo rm in g  G row th  F a c to r-a
Transforming growth facto r-a  (TG F-a), (a 48 amino acid polypeptide) interacts
with the same receptor as EGF (Marquardt et al 1984). It is a regulatory molecule 
capable o f affecting the same cell types, including epithelial cells that respond to
EGF (Todaro et al 1980). There is substantial evidence for the synthesis of TG F-a
during early fetal development but normal adult cells secrete little TGF- a  (Lee et al
1985) and (Twardzik et al 1985). This suggests that T G F-a may function as an 
embryonic version of EGF.
The binding of either T G F -a  or EGF to receptors on the surface of the tar get cells 
initiates a sequence o f cellular responses culminating in cell division (Downward et 
al 1984) and (Ullrich et al 1984). Over expression of T G F-a in transgenic mice 
has been demonstrated to lead to neoplasias and carcinomas (Sandgren e ta l 1990) 
and (Jhappan et al 1990). These finding indicate that T G F -a may play some role 
in the pathogenesis of certain types of cancer.
1.9 Action of T G F -a  in O v arian  C arc inom a Cell L ines
Expression of the EGF-r and secretion of T G F -a  occurred in 16 of 17 cell lines 
derived from ovarian carcinoma. Stim ulation of growth was observed after 
addition of T G F -a  in 8 of 13 cell lines and inhibition of growth was noted after
addition of neutralizing antibodies to T G F -a in 4 of 5 cell line (Kurt, Stromberg et
al 1992). This result gives evidence that autocrine growth via TGF-o/EGF-r may 
be common in development and/or progression of ovarian carcinoma.
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1.9.1 Involvem ent of T G F -a  an d  E G FR  in P rim a ry  O varian  
C ancer
EGF was detected in only 27.6% of ovarian cancers. T G F -a  was present in
88.5% and is common in all histological sub-divisions (owens et al 1991).
A coirelation between presence of EGF-r and expression of T G F -a has been
observed (Arteaga et al 1988) and (Bauknecht et al 1990). Thus, it is possible 
these particular growth factors have an autocrine or paracrine role in the growth
regulation of ovarian tumours. Antagonists to TGF-o/EGF-r autocrine mechanism
could be effective in treating certain human ovarian cancers (Ken-Ichiro et al
1991).
1.9.2 T ran sfo rm in g  G row th  Factor»j3
Transforming Growth Factor-13 (TGF-p) a 25,000 mol wt homodimeric protein,
was first isolated from media conditioned by transformed cells and identified as the 
protein responsible for the phenotypic transformation of marine fibroblasts (Delarco 
et al 1986). In addition to stimulating growth of fibroblastic cells in soft agar,
T G F-p has a variety o f actions including inhibition of epithelial cell growth
(M assague 1990). TG F-p has been reported to modulate several ovarian
functions such as FSH-dependent LH receptor induction in rat granulosa cells 
(Dodson et al 1987) and (Blair et al 1988). Three distinct molecular forms of
TGF-p have been identified in mammals: T G F -p l, TGF-P2 and TGF-P3. It has
been suggested that the development o f some human carcinomas might be due to a
loss of sensitivity to TGF-p (Roberts et al 1988).
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The cellular effects of TGF-j3s are multi-factorial and are dependent upon other 
factors, but in general, their effect upon epithelial cells is antimitotic (Sporn eta l
1986). TGF-ps consist of two identical 112 amino acid chains synthesized as part 
of a larger, biologically latent peptide (Sporn et al 1986 ; W akefield et al 1988), 
TGF-p can induce apoptosis in a fraction of ovarian cell lines and in tumour cells 
taken directly from patients (Havrilesky et al 1995).
TGF-p is secreted by thecal-interstitial cells from rat and bovine ovaries (Skinner et
al 1987). TG F-p is a regulator of granulosa cell function in vitro (Bendell and 
Dorrington 1988). Ovarian cancer cell proliferation might be due to loss of down 
regulation by polypeptides of the TG F-p family, although little is known about a
potential T G F p l autocrine loop in ovarian carcinoma cells (Berchuck et al 1990, 
Marth et al 1990). Retroviral ti'ansformation can result in greatly elevated levels of 
T G F -p  mRNA and TGF-p synthesis (Derynck et al 1986) and (Anzano et al
1985). TGF-p inhibited proliferation of normal ovarian epithelial cells between 40
- 70% (Berchuck et al 1991). Each chain is synthesised as the C-terminal domain 
of a 390 amino acid precursor that has the characteristics of a secretory polypeptide 
(it contains a hydrophobic signal sequence for translocation across the endoplasmic 
reticulum and is glycosylated) (Derynck et al 1985) and (Purchio et al 1988).
T G F -p  appears to play a role in normal ovarian function, particularly in the
regulation o f granulosa cell functions in response to follicle stimulating hormone
(Adashi et al 1989). The growth regulatory effects of TGF-P may be dependent
upon the presence of specific classes of binding proteins (Roberts et al 1991). In
addition, it has been shown that TG F-p is secreted in an inactive form non-
covalently bound to a portion of its precursor, from which it must be released to
produce the biologically active TGF-p.
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A lthough TG F-p initially was discovered due to its ability to induce the
transfoiTned phenotype in some normal cells, its predominant effect on most noimal 
epithelial cells, in vitro is inhibition of proliferation.
Expression of TG F-p is lost in a approximately 40% of ovarian cancers, but cells
taken directly from ascites fluid can still be inhibited by exogenous TGF-p in 95% 
of cases (Hurteau et al 1994).
1.9.3 Oncogenes
An oncogene is a gene the protein product of which can cause cancer under 
particular circumstances. Many oncogenes were originally found in vinises which 
had hi-jacked the genes from animal hosts. Oncogenes usually code for proteins 
regulating cell division. In the last decade more than 50 genes have been 
discovered which can cause the transfoi*mation of cells, be they cultured or within 
the tissues of transgenic animals. These genes ture dominantly transfomiing genes 
(Bishop 1987). The HER-2/neu (c-erb B2) proto-oncogene was first identified in 
studies in which NIH 3T3 cells were ti'ansformed with deoxyribonucleic acid from 
ethylnitroso urea-induced rat neuroblastomas (Padhy et al 1982).
The HER-2//ie« oncogene encodes a 185 kd cell surface protein (P I85) that has a 
cysteine-rich extra cellular dom ain, a m em brane-spanning region, and an 
intracellular domain that has intiinsic tyrosine kinase activity (Schechter et al 1985) 
O ver-expression o f H E R -2/neu, because o f gene am plification, occurs in 
approximately 25% to 30% of breast and ovarian ctu'cinomas (Slamon a/ 1987) 
and (Slamon et al 1989). HER-2//icw may be a useful target for immunotherapy 
with unconjugated antibodies and immunotoxins in ovarian and breast cancers that 
over-express this proto-oncogene (Rodriguez et al 1993).
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In contrast to oncogenes, there are a group of tumour suppressor genes whose 
protein products are essential to the elimination of transfoimed cells. Mutation and 
over-expression of the p53 gene is the most frequent genetic change to be 
described in human cancers so far (Nigro et al 1989). Over-expression of p53 has 
been observed in 50% of ovarian cancers and allelic deletion at the p53 locus in 25- 
55% of epithelial ovarian cancers, also loss of heterozygosity on 17q occurs in 
some sporadic ovarian cancer (Eccles et al 1990) and (Sato et al 1991).
In each of 9 cases studied from 17q-linked breast/ovarian cancer families, the allele 
losses affected the wild-type chromosome, consistent with a retinoblastoma like 
model in which the predisposing gene is a suppressor gene (Smith et al 1993).
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1.10 Aims and Objectives of Thesis
As can be seen from the preceding literature survey, onset of ovarian cancer may be 
the result o f promotion of transformed cells during post-ovulatory wound repair,
driven by the EG F/TG Fa system.
Alternatively, it may be due to loss of sensitivity to TGFp or, indeed, to some
com bination of the two. Additionally, previous work from our laboratory has 
shown that the EGFr-associated tyrosine kinase may become elevated in platinum 
resistant ovarian cancer cells.
As an in vitro approach to both developing new anti-ovarian cancer therapies and 
understanding more of the biology of this disease, tliis thesis examines:
1. The regulation of ovaiian cancer cell growth by EGF/TGFa.
2. The inhibition of growth by selective blocking of the EGFr-associated tyrosine
kinase.
3. The role of TGFp in mediating the growth inhibitoi-y effect of LH.
4. The relative effects of EG F/TG Fa and LH on the morphology of ovarian 
cancer cells.
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CHAPTER II
MATERIALS AND METHODS
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2.1 MATERIALS
2 . 1.1 Cell G row th  M edia
D ulbecco’s modification of Eagle’s medium (RPMI 1640) was originally supplied 
by Gibco. To eliminate the oestrogenic action of phenol red within the culture this 
was replaced by phenol red-free RPMI powder obtained from Sigma.
2 . 1.2 S upp lem en ts to Cell G row th  M edia
All other cell culture media and supplements were obtained from Gibco.
2.1.3 Cell C u ltu re  M ateria ls
Biofreeze Vials 
Dialysis Membrane
25,75, 175 cm2 T/C flasks
24 well FB plates 
Nalgene (Bottle Top Filter)
Sterile Acrodisc (0.2p.m Syringe Filters)
Tissue Culture Chambers
Nunc (Denmark)
Med International Ltd
Nunc
Corning
Nalge (Europe) Ltd 
Gemian Sciences 
Nunc
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2.1.4 Fine Chemicals
All chemicals used were of AnalaR grade or equivalent and were obtained from the 
following:
Bacitracin Sigma Chemical Co. Ld
Bovine Serum Albumin Sigma Chemical Co. Ld
Cycloheximide Sigma Chemical Co. Ld
Dextran Sigma Chemical Co. Ld
Dimethylsulphoxide May and Baker
Dithiothreitol Sigma Chemical Co. Ld
EDTA Fisons
2.1.5 Miscellaneous Materials
DNA (calf thymeus) type XV 
Hoechst 33258
Protein assay dye reagent concentrate 
RibonucleaseA
Scintillation fluid (Ultima-Flo)
ZM (252868)
Sigma Chemical Co. Ltd 
Sigma Chemical Co. Ltd 
Bio-Rad
Sigma Chemical Co. Ltd
Packard
Zeneca
Suppliers for any other specific materials or apparatus are indicated throughout the 
text.
2. 1.6 Hormones/Growth Factors
Gonadotrophin (LH) 
Gonadotrophin (FSH)
Marine Epidermal Growth Factor 
Oestrogens and Progesterone
Transforming Growth Factor-oc 
Transforming Growth Factor-pi
Sigma Chemical Co. Ld 
Sigma Chemical Co. Ld 
Biogenesis
Sigma Chemical Co. Ld 
Sigma Chemical Co. Ld
Sigma Chemical Co. Ld
35
Transfoiming Growth Factor-P-receptor 
TGF-p 1 Monoclonal antibody (TB21)
Sigma Chemical Co. Ld 
Bionostics Limited
2.1.7 EGF-receptor Study Reagents
EGF-receptor tyrosine kinase assay kit 
EGF-receptor Assay kit
Amers ham 
Vienna Lab
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2.2 BUFFERS AND SOLUTIONS
2.2.1 B u ffe rs
2.2.2. P h o sp h a te  B uffered  Saline (PBS) pH 7.2
170 mM NaCl
1 mM Na2HP0 4
2 mM KH2PO4.
2 .2 .3  ETN  B uffer
10 mM EDTA
lO m M Tris-H CL
100 mM Sodium Chloride, pH 7.
2 .2 .4  H a n k ’s M odified B uffer
Calcium Chloride 1.3 mM
Potassium Chloride 5.4 mM
Magnesium Chloride 0.5 mM
Magnesium Sulphate 0.5 mM
Sodium Chloride 137 mM
Sodium hydrogen carbonate 4 mM
Sodium dihydrogen orthophsphate 0.4 mM, pH 7.2 - 7.4
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2 .2 .5  H E B uffer pH  7.4
20 mM HEPES
1.5 mM EDTA 
10% Glycerol (v/v)
2 .2 .6  H ED  B uffer pH 7.4
HE Buffer plus 0.25 mM Dithiothreitol (DTT)
This was made fleshly on the day of use.
2.2.7 H E PE S B uffered  Saline pH  7.4 (HBS)
10 mM HEPES, 150 mM NaCl
2.3 C EL L C U LTU R E SO LU TIO N S
2.3.1 R ou tine  S u b -C u ltu re  M edium
RPMI 1640 medium with L-Glutamine; 10% (v/v) Fetal Calf Serum 
(FCS); 60 mg/ml Tylocine; 100 units/ml Penicillin; 50mg/ml 
Streptomycin.
2.3.2 D ex tran -C o a ted  C h arco a l
100 ml sterile PBS-A 
0.25% charcoal = 0.25g 
0.0025% dextran = 0.0025g
The mixture was stirred for 30 minutes, dispensed into 25 ml
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bottles and centrifuged. The supernatant was discarded and dialysed serum 
added to the pellet see section 2.3.3.
2.3.3 Dialysed Heat-Inactivated Dextran-Coated Charcoal
Stripped Serum (DHIDCCFCS)
100 mis of FCS was dialysed against four 1 litre changes of Hank’s
modified buffer over 48 hours at 4°C. Following dialysis the serum
was transferred to a glass container and heat inactivated for 45 mins
at 56°C. The serum was then cooled to 4°C and added to a pellet of
dextran coated charcoal (0.25% Charcoal w/v, 0.0025% Dextran w/v 
in 25 ml PBS-A which had been centrifuged for 30 min and the
supernatant removed). This solution was allowed to stir at 4°C for 30 min.
The dialysed serum was centrifuged for 30 min at 10,000 g, the supernatant
was filter-sterilised using 0.2 micron filters and stored at -20°C
2.3.4. Dialysing Tubing Preparation
Approximately 50 cm strips were boiled for 15 minutes in 
0.2% (w/v) sodium bicarbonate. After 15 minutes, the strips were 
rinsed in distilled water and stored in 50% methanol.
2.3.5 Versene
125 mM Sodium Chloride
2.7 mM Potassium Chloride
6.3 mM Di-Sodium hydrogen orthophosphate
3.2 mM Potassium dihydrogen orthophosphate
0.5 mM EDTA.
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2.3.6 T ry p s in /V e rse n e
40 ml Versene : 10 ml 0.25% (w/v) Trypsin Solution
2.3.7 Ceil C u ltu re  F reezing  M edium
RPMI 1640 medium with L-Glutamine; 10% FCS (v/v); 10%
Dimethyl Sulphoxide (v/v).
2.4 C E L L  C U L T U R E  M ETH O D S
2.4 .1  Cell L ines
OAW42 ovarian cancer cell line model (Wilson et al 1984) was kindly supplied by 
Dr. Anne Wilson (Derby). This cell line was derived from the malignant epithelial 
cells of a metastatic ovarian tumour.
PE O l and PE O lcddp ovarian cancer cell lines were derived from malignant 
effusions from a single ovarian cancer patient before and after her tumour became 
refractory to platinum therapy (Langdon et al 1988) was kindly supplied by Dr. 
Simon Langdon (ÏCRF, Edinburgh).
2.4.2 R ou tine  Cell C u ltu re
All cell lines were routinely grown at 37°C in a 5% CO2 atmosphere. All aseptic
manipulations were performed within the confines of a laminar air flow cabinet 
(Flow Labs). Initially routine subculture was perform ed using D ulbecco’s 
modification of Eagle’s medium (RPMI 1640) supplemented with 10% fetal calf 
serum (FCS), HEPES, pH 7.4 (10 mM), penicillin (100 units/ml), streptomycin 
(50 mg/ml) and Glutamine 10% (v/v). Cell medium was changed every two to
three days. Routine subculture was carried out using RPMI 1640 supplied as a
powder supplemented with 5% dialysed HIDCCFCS. All routine and experimental 
media were changed every 48-72 hours.
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2.4.3 Subculture Technique
Stocks of cells were grown routinely in 175 cm 2 plastic tissue culture flasks. After 
reaching 80-90% confluence,the medium was removed and the cells washed twice 
with 20 ml PBS at 37®C. 0.05% trypsin/versene solution (prewarmed to 37®C) 
was added to the culture flasks; 0.2 ml per well of a 24 well plate, 1 ml per 25 cm^ 
flask, 3 ml per 75 cm^ flask and 8 ml per 175 cm^ flask. The cells were incubated 
at 37®C in trypsin solution for 2-4 minutes. The tiypsinization reaction was
stopped by adding 2 volumes of fresh medium (37®C) followed by rapid pipetting
to ensure an even cell suspension. The cell suspension was then dispensed into 3- 
5 sterile culture flasks to which growth medium had been added before a final rapid 
pipetting ensured even distribution of the cells. Seeding of experimental plates and 
flasks was carried out using the technique described above with the following 
differences.
After the tiypsinization was stopped, the cell number per ml was counted using a 
haemocytometer and the suspension was diluted to the required concentration with 
routine medium. After 24-48 hours the routine medium was removed and the cells 
w ashed tw ice with prew arm ed PBS before the experim ental m edia and 
supplements were added. Initial plating was designed to achieve about 25%
confluence and cell numbers were 5x10"^ cells/well o f a 24 well plate, 5x1 ()6 
cells/25 cm2 plats and 5x10^ cells/well of a 96 well plates.
2.4.4 Mycoplasma Testing of Cell Lines
Mycoplasmas are a common and serious contamination of cell culture which can 
not be detected with the naked eye (Russel, 1975). They cause changes in 
metabolism, growth and viability which lead to variability o f results. Routine 
mycoplasma testing is therefore important to ensure eai'ly detection and 
treatment of any infection. An immunoassay mycoplasma detection kit (Boehringer 
Mannheim) was used for detection.To increase the sensitivity of the assay; the cells
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were incubated in antibiotic-and anti-PPLO-free medium for 72h prior to the 
im m unoassay being carried out. Firstly, m icrotiter plates were coated with 
antibodies to one of the four com monest mycoplasma strains {M ycoplasm a
arginini, MMyorhinis, A.laidawii, M .orale ) by incubating plates for 2h at 37®C in
coating solution. Nonspecific binding sites were blocked and the plates washed
before cell samples and controls were added and incubated overnight at 4®C.
Detection was carried out by incubating plates for 2h at 37®C with biotin-
conjugated antibodies against the mycoplasma strains mentioned above, followed 
by a Ih incubation with streptavidin-AP and a final Ih incubation with 4-nitro- 
phenylphosphate. Evaluation was canied out visually, a mycoplasma positive plate 
being yellow in colour whereas a mycoplasma negative plate is colourless. This 
procedure was carried out simultaneously on all the cell lines used in the laboratory 
every three months. If  any cell lines were infected all the growing cells were 
destroyed, as was any opened medium, supplement, buffer or plastic ware.
The cell culture unit and incubators were cleaned with Decon and 70% ethanol prior 
to fresh frozen stocks (frozen down prior to the last totally negative mycoplasma 
testing) being defrosted and seeded down. To help prevent mycoplasma infection, 
all medium was supplemented with anti-PPLO.
2.4.5 Preparation of Frozen Cell Stocks
To ensure that all experiments could be carried out on cells of a similar passage 
number and to protect against loss of a cell line due to contamination, frozen stocks 
of cells were prepared. One 180 cm^ flask of cells at about 70-80% confluence was
trypsinized as in section (2.4.3) and the reaction was stopped by adding 10 ml of 
routine medium. The cell suspension was transferred to a sterile universal 
container. The cells were pelleted by centrifugation at lOOOg for 2 minutes at 4®C
and the supernatant removed. The cells were resuspended in 4 ml of freezing 
medium as in section (2.3.7) and 1ml volumes were transferred to sterile Biofreeze
vials prior to being frozen at -70®C. They were then stored under liquid nitrogen.
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2.4.6 Recovery of Frozen Cells
To glow cells from frozen stocks the vials were thawed by placing in 37 ®C water 
bath for 5-10 minutes. The vials were removed from the water bath before all the 
ice had melted, and the cell suspension was transferred to a universal container to
which 10 ml of routine medium (37®C) had been added. The suspension was then 
centrifuged for 2 minutes at lOOOg before discarding the supernatant and 
resuspending the cells in medium at 37®C. The cell suspension was placed in a 75
cm2 flask and incubated at 37®C, as described in section (2.4.2).
2.4.7 SDS Lysis Buffer
The cell membrane had to be m ptured before many of the assays and procedures 
could be carried out. In the first method the cells were trypsinised as in section 
(2.4.3) and 10 ml o f routine m edium was added. The cell suspension was 
transferred to a sterile universal container.
This was then centrifuged for 2 minutes at lOOOg before discarding the supernatant 
and resuspending the pellet in 0.2% SDS in ETN buffer section (2.2.3) followed 
by incubation at 37®C for 30 minutes. This technique solubilises the DNA and 
denatures proteins, as well as solubilising the membranes.
2.5 EXPERIMENTAL METHODOLOGY
2.5.1 DNA Synthesis Experiments
Cells were plated down for 24 h in RPMI -f 10% FCS in 24 well F.B. plates. 
This medium was removed and the cells washed with two changes of sterile 
PBS-A (1ml). Experimental medium (Phenol Red Free Medium) + 5% dialysed 
HIDCCFCS, with or without hormones and growth factors were added to a final 
volume of 1 ml per well. At appropriate incubation times, wells were harvested by 
the removal of the medium and washing twice with PBS-A (1ml). To each well
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200|4l aliquots 0.1% (w/v) SDS in ETN buffer were added. Samples were
solubilised by incubation at 37®C for 30 minutes and stored at -20®C until the 
day of DNA assay.
2.5.2 Hoechst DNA Assay
The assay methodology is essentially that described by Leake & Habib (1987) and 
involves the intercalation of Hoechst 33258 into solubilised DNA resulting in a 
complex which fluoresces with a maximum emission at 450 nm. Solubilised 
samples were transferred to RT-30 tubes, and to each tube, 3 ml o f ETN buffer
containing Hoechst 33258 (100 ng/ml) and RNAase (5 |ig/ml) was added. The
tubes were then vortexed and incubated at 37®C for 15 minutes in the dark. 
Fluorescent enhancement at 450 nm was measured using a Hitachi-Perkin Elmer 
MPE-2A fluorescence spectrometer at an excitation wavelength of 360 nm with both 
slit widths set at 5 nm.
The results obtained were compared to a standard cuiwe range of calf thymus DNA 
o f 0-50 M-g/ml see section (2.5.4).
2.5.3 Preparation of Samples for Hoechst DNA Assay
Aliquots o f cell suspension were centrifuged at lOOOg for 5min at 4®C. The
supernatant was discarded and 200 p i of 0.1% (w/v) SDS in ETN buffer added.
The pellet was solubilised at 37®C for 30 mins. DNA was estimated using the 
standard curve (2.5.2).
2.5.4 Hoechst DNA Standard
DNA standards were prepared from a lOOpg/ml solution o f calf thymus DNA 
dissolved in ETN buffer which was diluted to give standard solutions containing 5,
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10, 15, 20, 30, 40, and 50pg/m l calf thymes DNA. The concentrations of these 
solution were verified by m easuring their absorbances at 260nm as lun it of 
absorbance at this wavelength corresponds to 50 pg/ml DNA. The standards were
stored for up to a month at -20®C.
2.6 BRADFORD PROTEIN ASSAY
2.6.1 Protein Standard
Bovine serum albumin (BSA) was used to create protein standard solutions ranging 
from 0-500 pg/ml. This was achieved by diluting a stock of Img/ml BSA with PBS 
or the same buffer as the samples to create standards of 0, 10, 20, 50, 100, 200, 
and 500 pg/m l protein content. The standards were stored at 4®C for up to two 
weeks.
2.6.2 Assay Protocol
This assay is based on the principle that there is a shift in maximum absorbance 
from 465 nm to 595 nm when protein binds to a solution of Coomassie Brilliant 
Blue G-250 (Bradford, 1976). Cells were lysed using the SDS lysis method 
(section 2.2.6). Dilutions of the samples were made (1:10 and 1:100). Biorad 
Bradford reagent was prepared by diluting commercial stock 1:6 and filtering 
through Whitman filter paper No. 1. The assay was carried out by placing 0.2 ml 
of each sample and standard into RT-30 tubes in duplicate and adding 0.8 ml of 
Bradford reagent. These were mixed gently and incubated at room temperature for 
30 minutes before the absorbance was read at 595 nm using a spectrophotometer 
(LKB ultra spec 4050). The absorbance of each standard was then plotted against 
the protein concentration of the standards to create a calibration curve, which was 
used to calculate the protein content of each of the samples.
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2.7 M TT ASSAY
MTT is a yellow water soluble tétrazolium dye that is reduced by live, but not dead, 
cells to a purple formazan product which is insoluble in aqueous solution. It can 
be used as a measure of cell viability (Mossmann, 1983) However, a number of 
factors can influence the reduction of MTT (Vistica et al 1991).
2.7.1 Experimental Protocol
2.7.2 Plating Down Cells
A sub-confluent monolayer culture was trypsinized and cells were collected in 
growth medium containing serum.
The cell suspension was centrifuged (200g, 5 minutes) to pellet cells. These were 
resuspended in gi'owth medium and cell number counted using haemocytometer. 
Cells were diluted to a density of 2.5-50x 10^ cells/ml, depending on the growth
rate of the cell line. Cell suspensions were transferred to 10 cm^ petri dishes using 
a multichannel pipette; 200 p i of suspension was added into each well of columns 
2-12 of a flat bottomed 96 well tissue culture plate (i.e. 88 wells per plate contained 
cells) starting with column 2 and ending with column 12 (see figure 8). 200 pi of 
growth medium was added to the 8 wells in columns. Plates were incubated in a 
humidified atmosphere at 37®C for 24 hours such that cells were in the exponential 
phase of growth at the time of replacing medium with that containing hormones, 
growth factors etc.
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Figure 8. Diagram of 96 well tissue culture plate
Blank Control B
9 10 11 123  4  5  6  7  821
47
2.7 .3  E stim ation  of S urviv ing  Cell N um bers
At the end o f the exposure period to experimental additives, the medium was 
removed from all wells containing cells and the cells were fed with 200 M-l of fresh
medium. 50 M-1 o f MTT (5 mg/ml in sterilised PBS) was added to all wells in 
columns 1 to 12.
Plates were wrapped in aluminium foil and incubated for 4 hours in a humidified 
atmosphere at 37°C. This was a minimum incubation time and plates can be left for 
up to 8 hours. The medium and M TT were then removed from the wells and the 
MTT-formazan crystals were dissolved by addition of 200 p i o f DMSO to all wells
in columns 1 to 12. Glycine buffer (pH 10.5) was added (25 pi per well) to all
wells. Absorbance was recorded at 540 nm immediately since the product was 
unstable. The wells in column 1, which contained medium, MTT but no cells were 
used to blank the plate reader.
2.7.4 Analysis of Results
A graph was plotted of absorbance (Y axis) against concentration (X axis). The 
mean absorbance reading from the 8 wells in column 2 was used as the control.
Any variations among the readings for these 8 wells reflect differences in initial 
plating of cells and/or growth conditions across the plate. By taking the mean value 
for each set of 8 wells, such variations should be eliminated.
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2.8 E PID E R M A L  G R O W T H  FA C T O R  R E C E P T O R  ASSAY
The Vienna Lab EOF receptor Assay (Vienna Labs, Vienna, Austria) provided 
materials for the quantitative measurement of Epidermal Growth Factor receptors 
(EGFr) in cell membrane fractions from cancer cell lines or human tumour tissues 
(e.g. breast, ovarian carcinoma). This kit has been carefully evaluated in several 
laboratories and shown to give exactly comparable quantitative results as the 
EGRTC standard Ligand Binding Assay for EGFr (Oberkanins et al 1995).
2.8.1 Components of the EGF-R “Scatchard” Assay
Assay Buffer (40ml)
Storage Buffer (2x concentrate; 20ml)
Tracer Dilution Buffer (15ml)
[125i]_e g F (lyophilized)
The lyophilised l^^I-EGF was reconstituted by adding 2.5 ml Tracer Dilution 
Buffer. Subsequent dilutions (into the colourless tubes) allow assay over a final 
concentration range of 0.1-4 n molar.
The kit also contained :
Reaction Tubes (colourless; 110 tubes)
Reaction Tubes with EGF (green label; 30 tubes *)
* Tubes contain lyphilized EGF resulting in a 200x excess over [l^^IJ-EGF 
at 1 nM during incubation to allow determination of non-specific binding.
Control (1 vial)
The Control contains lyophilized human placenta membranes. These were
reconstituted by adding 1 ml Assay Buffer (0-4°C) immediately prior to
analysis.
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Precipitation Reagent 1 (45 ml)
This was shaken well before use 
Precipitation Reagent 2 (45 ml)
Precipitation Reagent 3 (concentrate)
This was prepared as a working solution by adding H 2O to a final volume of
600 ml.
2 .8 .2  P rocessing  of Cell Sam ples
Cells (70-80% confluent), grown in 175 cm^ plastic flasks in routine medium were 
harvested and pelleted by centrifugation at 1000 g for 5 mins. The cell pellet was
then washed twice in ice-cold PBS-A and resuspended in 4 ml of HED buffer (10
mM Hepes, 1.5 mM EDTA, 0.5 mM Dithiothreitol, pH 7.4).
2.8.3 Cell H om ogen ization
Cells were mixed with a suitable homogenization buffer (10 mM Hepes, 50 mM 
sodium chloride, 0.1% (w/v) BSA, pH 7.0). Cells were homogenized using Ultra- 
turrax homogeniser followed by gently homogenization using a glass/glass tissue 
grinder for 2x10 second bursts to ensure an even suspension. The temperature of
the suspension was not allowed to rise above 8°C at any time.
2 .8 .4  S ep a ra tio n  of N uclei, M em branes, an d  C ytosol
Cell homogenates were centrifuged at 800 g for 15 min at 4°C to collect cell debris
and nuclei. The supernatant was further centrifuged at 50,000 g for 60 min at 4°C. 
The resulting supernatant (cytosol) was transferred into a fresh container.
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The pellet containing cellular membranes was resuspended in 400-500 pi assay
buffer. A homogeneous suspension was achieved by repeatedly pipetting through 
the tip of a micropipette.
The volume of the suspension was determined by the pipette. An equal volume of 
storage buffer was added (provided as a 2x concentrate).
An aliquot (25-50 pi) was rem oved for protein measurement. The membrane 
suspension was stored at -20°C.
2 .8 .5 Preparation of Reagents and Samples
The reaction tubes were allowed to warm up to room temperature (at least 30 min). 
Two green tubes for each sample to be analyzed were removed.
The package was tightly resealed and the remaining tubes were stored at 4°C.
A working solution of precipitation reagent 3 was prepared by dilution with H 2O,
to a total volume of 600 ml. Precipitation reagents 1,2 and 3 were kept at 0-4^C.
The lyophilized [l^^IJ-EGF (“Tracer”) was dissolved in 2.5 ml Tracer dilution
buffer at 0-4°C. Dilutions of this Tracer stock solution were prepared according to 
the following scheme :
“Tracer” Dilution C l C2 C3 C4 C5 C6 C l C8
Final [125i] .e GF  Cone 0.10 0.25 0.50 0.75 1.00 1.50 2.50 4.00nM
Tracer stock solution 20 50 100 150 500 300 500 800 pi
Tracer Dilution Buffer 1180 1150 1100 1050 2500 900 700 400 pi
Tracer dilutions C1-C8 were kept refrigerated (0-4°C) while performing the assay. 
The lyophilized control was resuspended in 1 ml assay buffer and carefully mixed
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by pipetting several times, and kept on ice until starting incubations with tracer 
dilution.
Samples were diluted with assay buffer to a concentration range of 0.3-1.5 mg
membrane protein per ml. A minimum of 750 p i of each diluted sample was
required for saturation analysis. Samples were mixed carefully by pipetting several 
times, for homogeneity. Diluted samples were kept on ice until starting incubations 
with tracer dilutions.
2.8.6 P ip e ttin g  Schem e
Eight colourless tubes were prepared (to determine “total binding”) (Tubes to 
receive C TC 8 as described on the previous page ) and two tubes with green label 
(to determine “unspecific binding”) (each containing In molar + 200-
fold unlabelled EGF) for each sample to be analyzed.
75 p i of each sample was dispensed into the eight colourless tubes and the two 
green tubes.
75 p i  o f each [^^^I]-EG F (“Tracer”) dilution was added to the appropriately 
labelledtubes.
75pl of tracer dilution C5 (final concentration In molar ^^SpgG F) was added to 
the tubes marked green.
2.8.7 In cu b a tio n  and  S ep ara tio n
Tubes were shaken gently and incubated at room temperature for 2 hours.
Whilst the experimental tubes were incubating, 3 different tubes for each final tracer
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concentration C1-C8 were counted in a gamma-counter for 1 min to determine cpm 
“Total counts (C1-C8)”.
Incubation was terminated by adding 300 pi precipitation reagent 1 to all tubes, 
(reagent was mixed by vortexing before use).
300 pi precipitation reagent 2 was added to all tubes and mixed by vortexing.
After 10 min, 2 ml precipitation reagent 3 was added to all tubes and mixed.
Tubes were centrifuged at 3.000 xg for 15 min at 4^0.
Supernatants were decanted (Tubes were placed in a tightly fitting foam rack which 
allowed multiple supernatants to be decanted simultaneously).
Pellets were washed by adding 2 ml precipitation reagent 3 to all tubes, briefly
vortexed and centrifuged at 3.000xg for 15 min at 4°C.
Supernatants were decanted and tubes were drained by standing them inverted on 
paper towels for 1-3 min, pellets were counted in a gamma-counter for 1 min.
2.8.8 Calculation of Results
To calculate maximum binding capacity and dissociation constant of EGFr in a 
sample the following parameters have to be known;
Total Binding (BT)
cpm of pellets in colourless tubes (1 tube per sample for each final Tracer 
concentration C1-C8)
Unspecific Binding (BU)
cpm of pellets in tubes marked green (mean of 2 tubes per sample)
Total Counts (T)
cpm of tubes before adding precipitation reagents (mean o f 3 tubes for each final 
Tracer concentration C1-C8)
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Protein Concentration
The protein concentration of the diluted sample which was incubated with Tracer 
dilution ([mg/ml] the respective value must be between 0.3-1.5)
The Maximum Binding Capacity of the membrane preparation as “fmol EGFr per 
mg membrane protein”.
x-intersection [fmol/tube] = fmol EGFr/mg membrane protein
Protein conc. [mg/ml]x 0.075
2.9 EGF RECEPTOR TYROSINE KINASE ENZYME ASSAY
Binding o f EGF to the receptor domain results in receptor dim erization and 
autophosphorylation and an activation of the tyrosine kinase activity of EGFr 
(Downward er a / 1984). The phosphorylated tyrosine residues of the EGFr are 
involved in binding enzymes containing SH2 or SH3 domains. Enzymes that bind 
to EG Fr phosphotyrosine residues include phosphatidyl inositol 3 kinase,
phosphlipase Cy and ras GTPase activating protein (Margolis et al 1992 and 
Ullrich et al 1990).
2.9.1 Substrate Buffer
A ready to use solution of 1.5 mM peptide in a buffer containing 135 mM HEPES, 
300 )iM sodium orthovanadate, 3 mM  dithiothreitol, 0.5% Triton X-100, 6% 
glycerol and 0.05% sodium azide pH7.4
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2.9 .2  M agnesium  A TP B uffer
A ready to use solution of 1.2 mM ATP in a buffer containing 30 mM Hepes, 72 
mM magnesium chloride and 0.05% sodium azide pH7.4.
2.9.3 E p id e rm al G row th  F ac to r (EG F)
Human recombinant epidermal growth factor (6|iM).
2.9.4 S top R eagen t
A ready to use solution of 300 mM orthophosphoric acid containing cfirosine red.
2 .9 .5  Peptide B inding P apers
Twenty sheets of peptide binding paper containing 12 assay discs (3.0m diameter) 
allowing 240 assay to be performed. Each disc is individually numbered.
2 .9 .6  Sam ple P rep a ra tio n
Samples of tissue or cells were homogenized in buffer containing 50mM Tris, 
Im M  MgCl2, 2mM EDTA, 20 [ig/ml soybean trypsin inhibitor and 50|ag/ml PMSF
(the latter two as protease inhibitors). A suitable buffer for solubilization and 
storage is 50 mM Hepes, 20% glycerol, 1% Triton X-100, 0.1% BSA, 0.05% 
sodium azide. Storage o f solubilised EGFr TK at -80°C was recommended by
Amersham. Apparent low values, obtained for concentrated samples may be due to 
interfering effects of some reagents used for sample preparation and competing 
enzyme activities in the sample (ATP hydrolyzing and proteolytic enzyme).
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The Kit manufacturer recommended that dilution may reduce or obviate these 
effects. Sample were diluted and assayed as described (2.9.9). Calculation of total 
apparent EGFr TK activity was obtained from consideration of the dilution factor 
and the extent of phosphorylation using the fonnula described on (2.9.11).
2.9.7 In c u b a tio n  C ond itions
The assay is designed to measure the incorporation of phosphorus-32 into peptide
at 30°C for a period of 30 minutes. The assay was linear for incubation times of up
to 45 minutes and incorporation of up to 20% of total ATP. Further incubation or 
incorporation may not be a linear and so was avoided.
2.9 .8  R eagen t P re p a ra tio n
All assay components were thawed and warmed to 3CPC before beginning the assay 
Once thawed, each was reconstituted thoroughly by swirling and inversion and 
placed on ice. Unused reagents were re-frozen and stored at -15 to -30°C.
The magnesium [32p] ATP buffer was prepared using a minimum of 9.25 KBq,
0.25.aCi, of [^^P] ATP per tube. Sufficient reagent 3 was dispensed to perform the 
number of assays required.
2 .9 .9  Assay P ro tocol
1. The reagents were prepared as described previously.
2. Tubes were labelled (in duplicate) for samples and placed in a rack.
3. 10 JU.1 of sample or buffer alone were pipetted into each appropriate tube.
4. 5|al of EGF were pipetted into each tube, or 5jLil water for no EGF control blanks
5. 10 |il of substrate buffer were pipetted into each tube.
6. The reaction were stai'ting by adding 5 p.1 of magnesium [^^P] ATP buffer.
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The contents of the tube was mixed.
7, The tubes were incubated at 30°C for 30 minutes. During the incubation time,
the binding discs were prepared. The required number of discs were cut out without 
removing discs from  the sheet and placed in a dry tray suitable for washing the 
papers.
8, 10 p-1 stop reagent was added to each tube to terminate the reaction.
9. The terminated reaction tubes were shaken. The tubes were microfuged for 15 
seconds to wash all reagent into base of the tube.
10. The phosphorylated peptide was separated as described in section (2.9.10).
2.9.10 S ep a ra tio n  P ro ced u re
Paper discs were provided in sheets of 12 disc. 30 (il of term inated reaction
mixture were pipetted into the centre of each paper disc. Each paper of 12 discs was 
washed as follows:
1. 250 ml 75 mM orthophosphoric acid or 1% acetic acid were added to the wash 
tray containing the paper discs, not more than 25 discs per wash tray.
The tray was rocked by hand for 2 minutes. Wash reagent was decanted and 
disposed of as phosphorus-32 liquid waste. A similar volume of wash reagent was 
added and the wash repeated once.
2. 250 ml of distilled water were added to each wash tray. The tray was rocked 
gently by hand for 2 minutes. Water was decanted and disposed of as phosphorus- 
32 liquid waste. A similar volume of water was added and the wash repeated once.
3. 200 ml of water was added to the wash tray. The tray was rocked gently to float 
the paper discs. Using forceps, each paper disc was removed from the paper sheet 
and the disc was placed in a 20 ml scintillation vial. W ater was disposed of as 
phosphorus-32 liquid waste and the paper sheet as phosphorus-32 solid waste.
4. 10 ml scintillant was added to each vial and was counted in an appropriate 
scintillation counter for phosphorus-32.
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2.9.11 Calculation of Results
The phosphorus-32 incorporated into the peptide was quantitatively measured as 
follows. In the presence of enzyme sample and EGF the [32P] counted on the
papers was the sum of non specific [32p] ATP binding, specific binding of 
phosphorylated peptide and binding of phosphorylated proteins in the cell extract 
(A). In the absence o f EGF and presence o f enzyme, the [^^P] counted on the 
papers was the sum o f non specific [32p] ATP binding, and non EGF dependent 
tyrosine kinase phosphorylation of the peptide and cell extract proteins (B).
In the absence of enzyme and presence of EGF the [^^P] counted on the papers is
due to non specific binding of [32p] ATP or its radiolytic decom position
products(C). EGF dependent tyrosine activity (EGFr TK) is therefore obtained 
from (A)-[(B)+(C)].
Calculation o f specific activity (R) of 1.2 mM magnesium [32p] ATP:
R -  cpm 5pi Mg[^^P]ATP cpm/nmole
6
Calculation of total phosphate (T) transferred to peptide and endogenous proteins 
30 pi spotted onto binding paper.
Total terminated volume 40 pi. T= (A- [(B) + (C)]) X 1.33.
Calculation of pmoles phosphate (P) transferred per minute 
P = T X 100 p moles/minute 
I X R
where I -  incubation time (min).
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2.10 E L E C T R O N  M IC R O S C O P IC  PR O C E D U R E
OAW 42 cells were studied for morphological change using Electron Microscopy. 
The cells were fixed for 1 hour using 2% glutaraldehyde in O.IM sodium 
cacodylate buffer at pH 7.2 (Sabatini et al 1963). The specimens were then given 
three 20 minutes washes in O.IM sodium cacodylate buffer at pH 7.2. Post­
fixation was carried out using 1% osmium tetroxide in O.IM sodium cacodylate 
buffer at pH 7.2. Following fixation the specimens were dehydrated with graded 
alcohol and embedded in Araldite (Glauert 1991). Ultrathin sections were cut with
a Diatom diamond knife and mounted on formvar coated 1000 pm  aperture grids.
The ultrathin sections were double stained with uranyl acetate (Stempak et al 1964) 
and lead citrate (Reynolds 1963). The stained sections were examined using a 
Zeiss E.M. 109 electron microscope at 50 kV and electronmicrographs taken on 
Ilford FP4 film.
2.11 T G F -B l W H O L E  C E L L  B IN D IN G  ASSAY
These experiments were performed to estimate the number and binding affinity of 
TGF-p receptors on the OAW42 cell surface. These ovarian epithelial cells were
seeded in routine medium onto a 24 well plate at initial density of 5 x 10'  ^cells/well 
and incubated at 37^0 overnight in a 5% CO2 atmosphere.
Cells were washed three times with sterile PBS-A followed by addition of RPMI 
medium containing 0.1% PBS-A and gi’own until almost confluent. The cells were 
then washed in three changes of sterile PBS-A /0.1% BSA. Cells were harvested 
from eight wells for protein and DNA assay.
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To each well 200 pi aliquots 0.1% (w/v) SDS in ETN buffer was added.
Samples were solubilised by incubation at 37°C for 30 minutes. Solubilised 
samples were transferred to eppendorf tubes and stored at -20°C until the day of 
DNA and protein assay.
To eight further wells, 200 p i binding buffer (^) containing 100 pM ^^^“I-TG F-pl 
were added. To another eight wells, 200 pi binding buffer containing 100 pM 1^ "^ 
I-TG F-pl+20 nM TG F-pl (unlabelled) were added.
Cells were incubated at 2 5 for 2 hours. Binding buffer was aspirated off and
disposed as radioactive waste. Cells were washed four times with ice-cold 
PB S/0.1% BSA.
0.1% SDS (500 pi) was added to each well, followed by incubation at 37°C for 30
minutes, then 200 pi aliquots of lysate from each well were pipetted into a gamma 
counter tube and counted.
The concentration of l^^T-TG F-pl were calculated as following; on the vial label
the following information was given:
Specific activity (SA) in Ci /m  mol =1080
Total activity (TA) in pCi = 10
The contents of the vial was reconstituted in a volume (v) of 100 p i of 0.17 mM 
HCL The concentration of TG F-pl in nM when reconstituted was:
TA/SA xlO'3
In this case 10/1080 xlO’  ^nM = 9.26 nM.
10 pCi in 100 pi
= 10^ pCi in 1 litre 
= 0.1 Ci/litre
= 0.1/1080 m mol/liter = 9.26 x lO'^M
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Therefore, the stock ^^^I-TGF-pl solution was diluted 1 in 9 in binding buffer to
produce a solution containing l^^I-T G F-pl at a concentration of approximately
lOOpM as required for the binding assay,
(•■^) Binding Buffer-Phenol red-free RPMI+0.1% BSA (no FCS).
2.12 STATISTICS
Student’s t test was used for statistical comparisons using a Macintosh computer 
(Instat program).
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C H A PT E R  III
R E S U L T S
62
3.1 CO RRELA TIO N  OF CELL NUMBER W ITH DNA CONTENT
In some experiments with the OAW 42 cell line, DNA synthesis was used as a 
means o f assessing cell survival and growth. Therefore, it is important to ensure 
that the level of DNA will reflect cell number. An initial experiment was carried out 
to show the conelation between DNA content and cell number.
Methods
The OAW 42 cell line was subcultured as in section 2.4.3. of the Methods chapter
using 25 cm^ tissue culture flasks. The cells were then allowed to plate down for 24
hours before the medium was renewed. Every 24 hours, the culture medium was 
removed from 2 flasks and the cell monolayer washed twice with PBS. The cells 
were harvested by trypsinisation, a sample of the harvested cells was removed and 
the number o f cells counted using a haemocytometer. The remaining cells were 
lysed and a DNA assay carried out as described in section 2.5.2. o f the Methods 
chapter.
Results
The relevance of using DNA concentration as a measure of cell number or cell 
proliferation can be validated by the production of a linear correlation curve between 
the two as seen in (fig.9).
Conclusions
Results in figure (9) show that there is good correlation between the concentration 
of DNA in a sample as determined by the Hoechst method and the number of cells 
in the same sample for all incubation times up to 96 hours.
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Figure 9. Correlation o f DNA concentration with cell number. This graph is an 
example of correlation between cell number and DNA concentration. Each column 
represents cell number (for a sample taken at 0, 24, 48, 72 or 96 hours, which was 
counted using a haemocytometer, the remainder of the same sample being assayed 
for DNA using the Hoechst Method as described in Methods chapter section 2.5.2.
DNA concentration versus cell number
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3.2 CORRELATION OF CELL NUMBER WITH MTT 
ABSORBANCE
In most experiments with the OAW 42 cell line and other cell lines, the MTT cell 
proliferation assay was used as a means of assessing cell survival and proliferation. 
Therefore, it was important to ensure that the level of MTT absorbance will reflect 
cell number.
Method
The OAW42 cell line was subcultured as in section 2.4.3. of the Methods chapter 
using 96 well tissue culture plates. Cells were plated down into individual plates at 
2500 cells/ml, the cells were then allowed to grow for 24 hours before the medium 
was changed with experimental medium (Phenol Red Free Medium) supplemented
with 5% DHIDCCFCS. One plate was taken after each 24 hours period and 50 pi
MTT dye (5 mg/ml in sterilised PBS) was added to each well at half of the plate, the 
rest of the cells were harvested after 24, 48, and 72 hours. The MTT assay carried 
out as described in section 2.7.3. of the Methods chapter and total cell number 
determined for each plate.
Results
The use of MTT absorbance as a measure of cell number or cell proliferation can be 
validated if there is a linear correlation when cell number, after different incubation 
times, is plotted against M TT absorbance. (Fig. 10) shows the correlation curve 
between the two.
Conclusions
Results in (fig. 10) show that there was good correlation between the MTT 
absorbance and the number of cells in the same sample.
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Figure 10. Correlation o f M TT absorbance with cell number. Each column 
represents increasing MTT absorbance versus cell number after 24, 48 or 72 hours. 
The MTT assay was carried out as described in section 2.7.3. o f Methods chapter. 
Values represent mean +/- SEM (bars) of triplicate experiments.
MTT absorbance versus cell number
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3.3 G R O W T H  R ESPO N SE TO EG F
The effect of various concentration of EGF on growth of ovarian cancer cell lines 
OAW42, PEO l and PEO lcddp was studied.
Method
The three cell lines OAW42, PE O l, and PEOlcddp were subcultured as in section 
2.4.3. of Methods chapter so that a 20% monolayer was formed within 3x96 well 
tissue culture plates per cell line as in section 2.7.2. of Methods chapter. The cells 
were then allowed to plate down for 24 hours before the routine medium was 
removed and the cells washed twice with PBS. Experimental medium (Phenol Red 
Free Medium) supplemented with 5% DHIDCCFCS in the presence of increasing 
concentrations of EGF (from 2.5 to 50 ng/ml) was added to each well. 8 wells were 
used for each concentration of EGF. Control cells were incubated in experimental 
medium without additive.
The cells were incubated at 37°C for 72 hours with changes o f experimental 
medium after 48 hours incubation. At each 24 hours time point one plate for each 
cell line was treated by adding 50 pi MTT dye (concentration 5 mg/ml in sterilised
PBS). The MTT assay was carried out as described in section 2.7.3. o f the 
Methods chapter.
Results
The results of the EGF sensitivity studies were expressed in the form of time 
course and dose response for each of OAW42, PEO l and PEO lcddp cells.
These are shown as the mean of 3 independent experiments and the standard errors 
of the mean are indicated by the error bars.
Figure (11) shows the OAW 42 cell growth response to EGF. At 24 hours there 
was decreased cell proliferation at all doses of EGF.
After 48 hours incubation, an increase in cell growth at different doses of EGF was 
observed, reaching a maximum of about 34% (p < 0.0001) above control at 10 
ng/ml dose.
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At 72 hours exposure, cells showed a dose-dependent increase reaching a 
maximum of cell proliferation about 21.8% (p = 0.0005) above control at 5 ng/ml 
dose.
Figure 12 shows that PEO l cell growth responds positively to the influence of 
EGF. At 24 hours exposure cells showed stim ulation o f growth reaching a 
maximum of 18.9% (p = 0.002) above control at 2.5 ng/ml dose.
After 48 hours exposure data showed similar results to those at 24 hours reaching a 
maximum of about 30.8% (p < 0.0001) above control at 2.5 ng/ml dose. At 72 
hours exposure, EGF still shows positive stimulation to the growth of PEO l cell 
line reaching a maximum of 33% (p = 0.05) above control at 10 ng/ml dose. EGF 
inhibit, growth of P E O l cell line at highest dose (over 50 ng/ml) at all period of 
incubations.
Figure 13 shows that PEO lcddp cell growth responds differently from the parent 
cell line PE O l to the influence of EGF. At 24 hours exposure cells demonstrate 
slight stimulation at a dose of 5 ng/ml about 6.3% (p = 0.03) above control. After 
48 hours exposure cell growth was inhibited by EGF reaching a maximum of 
16,7% (p = 0.001) at 50 ng/ml dose. At 72 hours exposure PEO lcddp cell growth 
was inhibited by EGF at all doses from 2.5 to 50 ng/ml reaching a maximum of 
about 31.9% (p < 0.0001) below control at 20 ng/ml dose.
Conclusion
The effect of EGF on OAW42 cells compaied with PEO l cells as can be se^ ^n from 
both results, the effect o f EGF on growth o f OAW 42 cells shows over 20% 
stimulation to the growth in between 5 to 10 ng/ml dose after 48 and 72 hours. 
PE O l cells shows over 30% stimulation to the growth at doses of 2.5 to 10 ng/ml. 
These comparison illustrates that both cell lines were growth stimulation to the 
effect of EGF at different doses.
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F igure IL  Growth response of the OAW42 ovarian cancer cell line to Epidermal 
growth factor (EGF). Cells were grown in experimental medium (Phenol Red Free 
Medium) supplemented with 5% DHIDCCFCS and exposed for 24, 48 or 72 
hours to increasing concentrations of EGF ( 2.5 to 50 ng/ml). Values represent 
mean +/- SEM (bars) of triplicate experiment.
Time course and dose response of OAW42
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F igure 12. Growth response of human ovarian cancer cells (PEO l) to epidermal 
growth factor (EGF). PEO l cells were growing in experimental medium (Phenol 
Red Free Medium) supplemented with 5% DHIDCCFCS and exposed for 24, 48 or 
72 hours to increasing concentrations of EGF (2.5 to 50 ng/ml). Values represent 
mean +/- SEM (bars) of triplicate experiments.
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F ig u re  13. Growth response of the ovarian cancer cell line (PEO lcddp) to 
epidermal growth factor (EGF). PEO lcddp cells were grown in experimental 
medium (Phenol Red Free Medium) supplemented with 5% DHIDCCFCS and 
exposed for 24, 48 or 72 hours to increasing concentrations of EGF (2.5 to 50 
ng/ml). Values represent mean +/- SEM (bars) of triplicate experiments.
Time course and dose response of PEOlcddp
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3.4 G R O W T H  R E SPO N SE  TO  T G F a
These experiments studied the effects o f various concentrations of T O P -a  on  
growth of both cell lines OAW42 and PEO l cells.
Method
The two cell lines were subcultured as in section 2.4.3. of Methods chapter so that 
a 20% monolayer was formed within 3x96 well tissue culture plates per cell line as
in section 2.7.2. of Method chapter. 4x10^ cells were added to each well, the cells 
were then allowed to plate down for 24 hours before the routine medium was 
removed and the cells washed twice with PBS. Experimental medium (Phenol Red 
Free Medium) supplemented with 5% DHIDCCFCS in the presence of increasing
concentrations of T G F-a (concentration range from 0.5 to 50 ng/ml) was added to
each well. 8 wells were used for each concentration of T G F-a. Control cells were 
incubated in experimental medium without additive. The cells were incubated at 
37®C for up to 72 hours with a change of experimental medium after 48 hours. 
After each 24 hour incubation period one plate for each cell line was treated by 
adding 50 (il MTT dye (5 mg/ml in sterilised PBS). The MTT assay was carried 
out as described in section 2.7.3. of the Methods chapter.
Results
The results of the T G F -a  sensitivity studies are expressed in the form of time
course and dose response histograms for both OAW42 and PE O l cell lines. These 
are shown as means of 3 independent experiments and the standard error of the 
means are indicated by the error bars.
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Figure 14 shows that OAW 42 cell growth responds positively but in a delayed
manner to the influence of T G F -a . At 24 hours there is no growth stimulation of
growth. After 48 hours exposure cells showed stimulation to the growth reaching 
a maximum of 9.3% (p = 0.0004) above contiol at 10 ng/ml and 20% (p = 0.0002) 
above control at 25 ng/ml after 72 hours exposure. The growth stimulation by
T G F a  was seen in PE O l cells figure 15 by 24 hours 35% (p < 0.0001) above
control at 25 ng/ml. After 48 hours exposure, stimulation of the cells were seen in
most o f T G F a  doses reaching a maximum of approximately 41% (p < 0.0001)
above control at 50 ng/ml T G F a dose. After 72 hours exposure cell proliferation
reaching a maximum of approximately 24.4% (p = 0.0002) above control at 10 
ng/ml dose.
Conclusion
Comment on growth effect of T G F a on OAW42 cells compared with PEO l cells as
can be seen from  both results, the effect of T G F a  on growth of OAW42 cells
shows growth stimulation over 48 hours reaching a maximum of 20% at 25 n g /m l. 
PE O l cells shows growth stimulation at 24, 48, and 72 hours with a maximum of 
41% at 50 ng/ml dose.
These comparison illustrates that both cell lines were growth stimulation to the 
different doses of T G F a but PE O l cells shows more stimulation to influence of
T G Fa than OAW42 cells.
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F ig u re  14. Growth response of human ovarian cancer cells (OAW 42) to 
transforming growth factor-a (TG F-a). OAW42 cells were grown in experimental 
medium (Phenol Red Free Medium) supplemented with 5% DHIDCCFCS and 
exposed for 24, 48 or 72 hours to increasing concentrations of T G F -a (0.5 to 50 
ng/ml). Values represent mean +/- SEM (bars) of triplicate experiments.
Time course and dose response of OAW42
cells to TGFa
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F ig u re  15. Growth response o f human ovarian cancer (PEO l) to transforming 
growth factor-a (TGF-a). PEO l cells were grown in experimental medium (Phenol 
Red Free Medium) supplemented with 5% DHIDCCFCS and exposed for 24, 48 or 
72 hours to increasing concentrations of TG F-a (0.5 to 50 ng/ml). Values represent 
mean +/- SEM (bars) of triplicate experiments.
Time course and dose response of PE01
cells to TGFa
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3.5 G R O W T H  R E SPO N SE  TO  T G F -p l
The effects of vaiious concenüations of TGF-Pi on growth of the OAW42 ovarian 
cancer cell line were studied by measuring cell numbers in terms of DNA content.
Method
OAW42 cells were subcultured using 24 well tissue culture plates.
The cells were then allowed to plate down for 24 hours before the routine medium 
was removed and the cells washed twice with PBS. Experimental medium (phenol 
Red-Free M edium supplem ented with 5% DHIDCCFCS) in the presence of
increasing concentrations of TG F-pl concentration range (from 0.05 to 5 ng/ml)
was added to each well. 4 wells were used for each concentration of TG F-pl. 
Control cells were incubated in experimental medium without additive. The cells 
were incubated at 37 °C  for 96 hours with changes of experimental medium each 48 
hours. The culture medium was removed and the cell monolayer were washed twice 
with PBS. The cells were harvested by trypsinisation and lysed and DNA assay 
carried out as described in section 2.5.2. of the Methods chapter.
Results
The results of the TG F-Pl sensitivity studies are expressed in the form o f a dose
response curve. Figure 16 illustrates the dose response of the OAW 42 cell line. 
These are shown as means of 3 independent experiments and the standard error of 
the mean is indicated by the error bars.
Conclusions
OAW 42 cells ai'e sensitive to increasing concentrations (from 0.05 to 5 ng/ml) of
T G Fpi over 96 hours exposure. There was a significant decrease of DNA content
(33.5% and 35.9% at 1.0 and 5.0 ng/ml, respectively) p < 0.05 after 96 hours 
incubation period compared with control cells over the same time .
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F ig u re  16. Growth response o f OAW 42 ovarian cancer cells to transforming 
growth factor-pi (TGF-Pl). Cells were growing in experimental medium (Phenol 
Red Free Medium) supplemented with 5% and exposed for 96 hours to increasing 
concentrations of T G F-pl (0.05 to 5 ng/ml). Values represent mean +/- SEM (bars) 
of triplicate experiments.
Dose response of OAW42 cells to TGFp1
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3.6 G R O W T H  R ESPO N SE TO  LH
The effects of various concentration of Luteinizing honnone (LH) on growth of 
both cell lines OAW42 and PEOl cells were studied.
Method
The two cell lines were subcultured as in section 2.4.3. o f the Methods chapter so 
that a 20% monolayer was formed within 3x96 well tissue culture plates per cell 
line as in section 2.7.2. of the Methods chapter. The cells were then allowed to 
plate down for 24 hours before the routine medium was rem oved and the cells 
w ashed tw ice with PBS. Experim ental medium (Phenol Red Free Medium) 
supplemented with 5% DHIDCCFCS in the presence of increasing concentration of 
LH, concentration range (from 2.0 to 60 iu/i) was added to each well. 8 wells were 
used for each concentration of LH. Control cells were incubated in experimental 
medium without additive. The cells were incubated at 37 °C for a maximum of 72 
hours with changes o f experimental medium each 48 hours. After each 24 hours 
incubation, one plate for each cell line was treated by adding 50 (il MTT dye
concentration (5 mg/ml in sterilised PBS). The MTT assay carried out as described 
in section 2.7.3. of the Methods chapter.
Results
The results of the LH sensitivity studies are in the form of time course and dose 
response curves for the OAW42 and PEO l cell lines. These results are shown as 
the mean o f 3 independent experiments and the standard errors of the mean are 
indicated by the error bars.
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Conclusions
The growth o f OAW 42 cells and PE O l cell is inhibited  by increasing 
concentrations of LH (from 2 to 60 iu/1) over 72 hours exposure.
Figure 17 shows the data for OAW42 cells.
At 24 hours the data showed a slight rise in cell proliferation at a dose of 10 iuA and 
inhibition of cell growth of 21.3% (p = 0.008) below control level at 60 iu/1 dose. 
After 48 hours exposure, OAW 42 cells showed a greater inhibition of growth 
reaching a maximum of 32% (p < 0.0001) below control levels at 60 iu/1 dose.
After 72 hours exposure OAW42 cells showed the same result as at 48 hours of 
time course.
Figure 18 shows the data for PE O l cells. At 24 hours the data showed a dose- 
dependent inhibition reaching a maximum at 60 iu/1 dose of 34.2% (p = 0.0005) 
below control cell growth.
PEO l cells after 48 hours exposure showed similar result as at 24 hours exposure 
with increasing inhibition of growth, reaching a maximum of 26.9% (p = 0.001) 
below of control level at 60 iu/1 dose.
After 72 hours exposure PEO l cells showed slight stimulation o f growth at lower 
dose of LH and highest inhibition of 32% (p < 0.0001) below control level at 60 
iu/1 dose.
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F ig u re  17. Growth response o f human ovarian cancer cells OAW 42 to 
Luteinizing hormone (LH). OAW42 cells were grown in experimental medium 
(Phenol Red Free Medium) supplemented with 5% DHIDCCFCS and exposed for 
24, 48 or 72 hours to increasing concentrations of LH (2 to 60 iu/1). Values 
represent mean +/- SEM (bars) of triplicate experiments.
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Figure 18. Growth response of human ovarian cancer cells PE O l to Luteinizing 
hormone (LH). PEO l cells were grown in experimental medium (Phenol Red Free 
Medium) supplemented with 5% DHIDCCFCS and exposed for 24, 48 or 72 hours 
to increasing concentrations of LH (2 to 60 iu/1). Values represent mean +/- SEM 
(bars) of triplicate experiments.
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3.7 STUDIES W ITH  ANTI-TGF-|31 ANTIBODY
Growth effects of LH and anti-TGF-pl antibody in OAW42 cells.
Method
OAW 42 cells were subcultured as in section 2.4.3. of the Methods section. Cells
(2x10^ cells/well) were added to each well of a 24 well tissue culture plates. The
cells were then allowed to plate down for 24 hours before the routine medium was 
removed and the cells washed twice with PBS. Experimental medium (Phenol Red 
Free Medium) supplemented with 5% DHIDCCFCS in presence of LH (40 iu/1) or
LH + TGF-p 1-antibody (5 or 30 p.1) was added to each well. 2 wells were used for
each condition. Control cells were incubated in experimental medium without
additive. The cells were incubated at 37°C for 48 hours. The culture medium was
removed and the cell monolayer were washed twice with PBS. The cells were 
harvested by trypsinization, lysed and DNA assay carried out as described in 
section 2.5.2. of the Methods chapter.
Results
The results of incubation of OAW42 cells in experimental medium containing LH
+/- anti-TGF-pl antibody are expressed relative to those in control medium.
These results are shown as the mean of 2 independent experiments and the standard 
errors of the mean are indicated by the error bars Figure 19.
Conclusions
Previous studies had shown that the maximum inhibition of the growth of OAW42 
cells was at a dose of 40 iu/1 LH.
Coincubation of LH (40 iu/1) with the anti-TGF- p 1 antibody at 5 fil/ml essentially 
blocked the anti-proliferative effect of LH alone. A Further increase in the 
concentration of antibody up to 30 fil/ml completely reversed the cytostatic effect of
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LH and induced growth above the level o f control, suggesting that under control 
conditions, growth may be partially blocked by some endogenous TGFp-like 
activity. LH alone significantly inhibits growth of OAW42 cells. In the presence 
of 5 fig/ml anti-TGFp antibody, this growth inhibition appears to be reversed 
although there is no significant difference between either LH alone and LH + 5 
fig/ml anti-TGFp antibody and control. Increasing the concentration of antibody
present in the culture medium, caused a stimulatory effect. Thus, 30 jal/ml of 
antibody was enough to overcome the inhibitory action of LH and, indeed allowed 
growth above control, suggesting that T G F -p l acts as an autocrine growth 
inhibitory factor in this cell line.
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F ig u re  19. Growth effects of LH and anti-T G Ppi antibody in OAW 42 cells. 
Cells were grown in experimental medium supplemented with 5% DHIDCCFCS 
and exposed for 48 hours to LH (40 iuA) +/- anti-TGFp 1 antibody (5 or 30 |al/ml). 
Values represent mean +/-SEM (bars) of duplicate experiments.
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3.8 TH E IN TERA CTIO N  BETW EEN EGF, LH AND FSH
The ability o f EGF to modulate the growth regulation of OAW 42 cells by the 
gonadotrophins LH and FSH was studied over 96 hours.
M eth o d
OAW 42 cells were subcultured using 24 well tissue culture plates, 2x10^
cells/well. The cells were then allowed to plate down for 24 hours before the 
routine medium was removed and the cells washed twice with PBS. Experimental 
medium (Phenol Red Free Medium) supplemented with 5% DHIDCCFCS in the 
presence of various combinations of EGF (10 ng/ml), LH (40 iu/1) and FSH (30 
iu/1). Control cells were incubated in experimental medium without additives.
The cells were incubated at 37®C for 96 hours with changes of medium and drugs 
each 48 hours. The culture medium was removed and the cell monolayer were 
washed twice with PBS. Cells were harvested by trypsinization and lysed and the 
DNA assay carried out as described in section 2,5.2. of Methods chapter.
R e s u lts
The interactions between EGF, LH, and FSH are shown as means of 3 
independent experiments in figure (20) and the standard errors of the mean are 
indicated by the error bars.
C o n c lu s io n s
As can be seen from figure 20, LH alone caused the expected growth inhibition, 
whereas FSH alone caused no significant change in growth over 96 hours. EGF 
alone induced a small growth stimulation about 5% (p = 0.02) that was reversed by 
LH (and by LH -f FSH) but not by FSH alone.
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Figure 20. The effect of EGF with both gonadotrophin hormone LH and FSH on 
growth o f OAW 42 human ovarian cancer cell line. Cells were grown in 
experim ental m edium  (Phenol Red Free M edium ) supplem ented with 5% 
DHIDCCFCS and exposed for 96 hours to (EGF 10 ng/ml, LH 40 iu/1 , and FSH 
30 iu/1). Values represent mean +/- SEM (bars) of triplicate experiments.
D ose  r e sp on se  of OAW42 ce l ls  to EGF, LH 
and FSH
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3.9 G R O W T H  R ESPO N SE TO  O E ST R A D IO L  AND 
PR O G E ST E R O N E
The mature ovary actively synthesizes and secretes a variety of hormones. Among 
these are the sex steroids, which include oestrogens and, during the luteal phase of 
the cycle, progesterone. It was of interest to establish whether the three ovarian 
cancer cell lines (OAW42, P E O l, and PEO lcddp) were themselves sensitive to 
oestrogen and progesterone.
M eth o d
The three cell lines were sub cultured as in section 2.4.3. of the Methods chapter by 
adding sufficient cells 4x10^ cells/well to form a 20% monolayer within 3x96 well 
tissue culture plates per cell line. The cells were then allowed to plate down for 24 
hours before the routine medium was removed and the cells washed twice with 
PBS. Experimental medium containing different concentrations of E2, and Pg
(concentration range from IxlO '^^M  to Ix lO ’^M) was added to each well. The E2
and Pg were dissolved in absolute alcohol to form a stock solution of IxlO ’^M 
which could then be diluted into culture medium to produce working concentrations 
o f lOrS M. 8 wells were used for each dose concentrations and control. Control 
cells were incubated in experimental medium without hormone additive but with the 
same final absolute alcohol concentration as the experimental medium. The cells 
were incubated at 37 °C for 72 hours with changes of experimental medium after 48 
hours incubation.
After every 24 hours exposure, one plate for each cell line was treated by adding 50 
}il M TT dye (concentration 5 mg/ml in sterilised PBS). The MTT assay was carried 
out as described in section 2.7.3. of the Methods chapter.
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R e s u lts
The results of the E2 and Pg sensitivity studies are expressed in the form of a time
course and dose response for OAW42, PEO l and PEOlcddp cells.
These are shown as mean of 3 independent experiments and the standard errors of 
the mean are indicated by the error bars.
Figure 21 shows growth o f the OAW 42 cells is inhibited by increasing 
concentrations of E2 (from lO 'H  to lO'^M) over 72 hours exposure. At 24 hours 
data showed a significant, dose-related inhibition of growth reaching a maximum 
effect at 10“^  M E2 of 53.4% (p < 0.0001) with respect to control. After 48 hours,
exposure cells demonstrated similar results to 24 hours, reaching a maximum of 
52.9% (p < 0.0001) inhibition at 10"^ M dose. At 72 hours exposure, data showed
highly significant inhibition of cell proliferation at 10"^M E2 giving growth of 59% 
(p = 0.0006) below control.
Figure 22 shows growth of the PE O l cells is inhibited by different doses of E 2 at 
all periods of incubation with significant decrease of the cell inhibition reaching a 
maximum of 32.3% (p < 0.0001) below control at 10-6 dose, 45.5% (p < 0.0001) 
at lO'^M dose and 29.8% (p < 0.0001) below control at 10"^M dose after 24, 48 
and 72 hours exposure respectively.
PEO lcddp in figure 23 shows similar results to those for OAW42 and PEO l cells 
with an inhibition of proliferation at lO'^M of 29.1% (p = 0.003) below control at
48 hours exposure and 25.3% (p = 0.006) after 72 hours exposure at lO'^M. 
C o n c lu s io n
E2 has a more dramatic inhibition of the growth of OAW42 cells compared with 
P E O l cells. The effect o f E2 on growth of OAW 42 cells shows over 50% 
inhibition to the growth in between 10 '? to 1 0 " after 24, 48, and 72 hours.
PEO l cells shows growth inhibition over 25% at 10‘^M dose of E2 after 24, 48, 
and 72 hours.
P ro g es te ro n e
The results of the Pg sensitivity studies are expressed in the form of time course 
and dose response to OAW42, PE O l, and PEO lcddp cells. These aie shown as 
mean of 3 independent experiments and the standard deviation is indicated by the 
error bars.
R e s u lts
Figure 24 shows the growth of OAW 42 cells is inhibited by increasing 
concentrations of Pg (from 10"l^ to 10"^M) over 72 hours exposure. At 24 hours 
data showed inhibition of growth reaching a maximum effect of 40.4% (p = 
0.0001) below control cell growth at lO'^M dose. After 48 hours exposure to Pg,
inhibition of cell growth was noted for doses lO 'l^ M and above, with a maximum
inhibition of 38.2% (p = 0.3) at 10‘^M dose. After 72 hours exposure, the results
showed inhibition of growth reaching a maximum of 42% (p = 0.009) at lO'^M 
dose. After 24 hours exposure PE O l cells were inhibited at all doses of Pg, as can 
seen from figure 25, reaching a maximum of 40.2% (p = 0.004) at 10"^M dose. 
After 48 hours incubation, cells were growth inhibited reaching a maximum of 
34.1% (p = 0.003) below control at lO '^M  dose. A fter 72 hours exposure, 
inhibition o f cell growth was seen at all doses of Pg, reaching a maximum of 
44.4% (p < 0.0001) at 10“^ M dose.
Figure 26 shows that PEO lcddp cell growth was only inhibited by Pg at 10"8 and
lO'^M dose, reaching a maximum of 26.6% (p = 0.003) and 34.8% (P == 0.002)
below control cell growth after 24 hours. After 48 hours exposure, inhibition o f cell
growth was seen for all doses reaching a maximum of 24.5% (p = 0.005) at 10
dose. After 72 hours incubation the growth of PEO lcddp cells was inhibited at all 
doses, reaching a maximum of 30.2% (p = 0.0001) below control cell growth
at lO'^M dose of Pg.
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Conclusion
The effect o f Pg on the growth of OAW42 cells was compared with PEO l and 
PEO lcddp cells as can be seen from the results, the effect of Pg on growth of 
OAW 42 cells shows over 40% inhibition to the growth at lO'^M after 24, 48, and
72 hours. PEO l cells shows growth inhibition from 34 to 44% at lO'^M after 24,
48, and 72 hours. PEO lcddp cells shows growth inhibition over 30% at 10“^M
after 24, 48, and 72 hours, these comparison illustrates that Pg more effected on 
growth of OAW42 and PEO l cells than PEOlcddp cell line.
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F igu re  21. Dose response of OAW 42 human ovarian cancer cells to oestradiol. 
OAW 42 cells were grown in experimental medium (Phenol Red Free Medium) 
supplem ented with 5% DHIDCCFCS and exposed for 24, 48 or 72 hours to 
increasing concentrations (ICfll to 10‘^M) of 17p-oestradiol (E2). Values represent
mean +/- SEM (bars) of triplicate experiments.
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F ig u re  22. Dose response of PE O l human ovarian cancer cells to oestradiol. 
PEO l cells were grown in experimental medium (Phenol Red Free Medium) 
supplemented with 5% DHIDCCFCS and exposed for 24, 48 or 72 hours to
increasing concentrations (lO ’l^ to lO'^M) of 17p-oestradiol (E2). Values represent 
mean +/- SEM (bars) of triplicate experiments.
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Figure 23. Dose response of PEO lcddp human ovarian cancer cells to oestradiol. 
PEO lcddp cells were grown in experimental medium (Phenol Red Free Medium) 
supplem ented with 5% DHIDCCFCS and exposed for 24, 48 or 72 hours to
increasing concentrations (lO 'H  to lO'^M) of 17p-oestradiol (E2). Values represent 
mean +/- SEM (bars) of triplicate experiments.
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F ig u re  24. Dose response of human ovarian cancer cells to Pg. OAW 42 cells 
were grown in experimental medium (Phenol Red Free Medium) supplemented 
with 5% DHIDCCFCS and exposed for 24, 48 or 72 hours to increasing 
concentrations (lO '^l to lO'^M) of progesterone (Pg) ). Values represent mean +/- 
SEM (bars) of triplicate experiments.
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F ig u re  25. Dose response o f human ovarian cancer cells to Pg. PE O l cells 
growing in experimental medium (Phenol Red Free Medium) supplemented with 
5% DHIDCCFCS and exposed for 24, 48 or 72 hours to increasing concentrations 
(lO '^l to lO'^M) of progesterone (Pg). Values represent mean +/- SEM (bars) of 
triplicate experiments.
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F igu re  26. Dose response of human ovarian cancer cells to Pg. PEO lcddp cells 
were growing in experimental medium (Phenol Red Free Medium) supplemented 
with 5% DHIDCCFCS and exposed for 24, 48 or 72 hours to increasing 
concentrations (10‘H to lO’^M) o f progesterone (Pg). Values represent mean +/- 
SEM (bars) of triplicate experiments.
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3.10 E PID E R M A L  G R O W T H  FA C T O R  R E C E PT O R
The EGFr is the common cell surface receptor for a family of closely related growth 
factors (EG F-iike factors) including epiderm al growth factor (EGF), and
transforming growth factor alpha (TG Fa). EGFr has been noticed in malignancies
of various organs. In ovarian carcinomas EGFr, has been said to be associated with 
tum our sensitivity to cisplatin (Bauknecht et al 1990). A positive EGFr is 
associated with increased remission rates after cis-platin therapy.
M eth o d
The Vienna lab EGFr ‘Scatchard assay’ kit (see Methods chapter 2.8) provides 
materials for the quantitative measurement of epidermal growth factor receptor 
(EGFr).
Radio receptor assay of EGFr in ovarian tumour cell lines was carried out through 
incubation of cell membrane suspension (prepared as described in Methods 2.8.7).
Membrane suspension (75|al) was incubated with 75|al l^^I-EGF in the presence or
absence of 1 nM unlabelled EGF for 2 hours at room temperature following the 
procedure illustrated in section 2.10. of the Methods chapter.
R e s u lts
Results of Scatchard analysis of EGFr content of the two cell lines are reported in 
Table ( 3 ).
Table ( 3 ) .  Epidermal growth factor receptor levels in OAW42 and PEOl human 
ovarian cancer cell lines.
Cells Kd (nM) Fmol/mg protein
OAW 42 0.833 24.8
+/- 0.019 +Z-5.9
PE O l 0.840 21.5
+A0.023  +/-1.7
Values represent mean +/- SD triplicate experiments.
Kd -  dissociation constant.
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C o n c lu s io n
OAW 42 and PE O l cells exhibited high affinity EGF receptor with a maximum 
binding capacity of 24.8 and 21.5 fmol/mg protein and dissociation constant, 0.833 
and 0.840 nM respectively as can seen in Table (3). Scatchard plots of EGFr in 
both cell lines are illustrated in (Fig. 27, 28). Compai'ing these results with Owens 
results for clinical tissue, it follows that the EGFr in the two cell lines is very 
similar to that detected in EGFr positive ovarian cancer biopsies. EGF was present 
in 39.7% of samples o f ovarian tumours with high affinity (Kd < 1 nM) and low 
affinity (Kd > 1 nM) Owens et al (1991). The two cell lines are very similar in 
EGFr concenti’ation comparing to the PEO l value, 22 fmol/mg protein (Kd 2.8 nM) 
C ic w e ta l  (1992).
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F ig u re  27. Radioreceptor assay o f epidermal growth factor receptor (EGFr) in 
human ovarian cancer cells. Scatchard plot is shown of specific high affinity EGF 
binding in OAW42 cells. Each data point was performed in triplicate experiments. 
Botli dissociation constant (Kd) and concentration values are reported in Table 3.
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F igu re  28. Radioreceptor assay of epidermal growth factor receptor (EGFr) in 
human ovarian cancer cells. Scatchard plots of specific high affinity EGF binding in 
PE O l cells. Each data point was perform ed in triplicate experiments. Both 
dissociation constant (Kd) and concentration values are reported in Table 3.
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3.11 EG F-R EC PTO R  TYROSINE KINASE STUDIES
The epidermal growth factor receptor (EGFr) has been recognised as a marker of 
poor prognosis in some gynecologic cancers. Amersham have developed a reagent 
which is said to measure the tyrosine kinase activity of the solublised receptor. 
This kit was used to detect functional EGF receptor in OAW42 ovarian cancer cells 
on the assumption that only EGF receptor possessing TK activity can be functional.
M eth o d
OAW 42 cells were subcultured as in section 2.4.3. of the Methods chapter. Cells 
were washed, lysed and fractionated as in section 2.8.3. Methods chapter. Enzyme
reactions were done in a total volume of 40 |il containing 50 mM HEPES (pH 7.4), 
1 mM MgCl2, 2 mM  EDTA, 20 jig/ml soybean trypsin inhibitor, 50 fig/ml PMSF, 
5 |il o f ATP containing 0.25 |iC i of [32p] ATP, varying concentrations of Zeneca 
inhibitor (ZM 252868), and 10 |i.l of substrate buffer peptide. The reaction was 
initiated by addition of the labelled ATP. After 30 minutes incubation at 30°C the 
reaction was terminated by addition o f 10 |ul stop reagent (solution of 300 mM
orthophosphoric acid containing carmosine red) and the solution was passed 
through a 2.5 cm phosphocellulose filter disk that bound the peptide. The filter was 
washed five times with 1% acetic acid and distilled water. The filters were placed 
in vials with 5 ml of scintillation fluid and counted.
S u m m ary  o f the  assay
EG FrTK ,M g++
[Peptide] + [y-32p]ATp — ----------------►  [32p] peptide + ADP
EGF 1Apply to paperIWash and count
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Results
Inhibition of enzyme activity of EGF-receptor tyrosine kinase by ZM (252868) is 
expressed in the form of dose response curve. Fig. 29 illustrates the dose response 
of OAW 42 cells. These are shown as means of 3 independent experiments and the 
standard error of the mean are indicated by the eiTor bai's.
Figure 29 shows the inhibition of OAW 42 tyrosine kinase enzyme activity by 
increasing concentration o f ZM from (0.1 to 3.0 fiM) reached a maximum of a
significant inhibition about 88% below control cell enzyme activity at the highest 
dose o f ZM (p = 0.0008).
This indicates that blocking EGFr activity could be a possible therapeutic approach 
for EGFr +ve ovarian cancer.
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Figure 29. The effect of tyrosine Kinase inhibitor ZM (252868) on EGF-receptor 
enzyme activity secreted by OAW42 cells. Cells were exposed for 30 minutes to
increasing concentrations of ZM inhibitor (0.1 to 3.0 pM). Values represent SEM
(bars) of triplicate experiments.
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3.12 GROW TH RESPONSE TO TK I
The effect of various concentration of Zeneca Inhibitor (ZM 252868) on growth of 
ovarian cancer cell lines OAW42, PEO l, and PEOlcddp.
M eth o d
All three cell lines were subcultured as in section 2.4.3. of Methods chapter so that 
a 20% monolayer was formed within 3x96 well tissue culture plates per cell line as 
in section 2.7.2. of Methods Section. The cells were then allowed to plate down for 
24 hours before the routine medium was removed and the cells washed twice with 
PBS. Experimental medium (Phenol Red-Free Medium) supplemented with 5% 
DHIDCCFCS in the presence of increasing concentrations of TKI (ZM 252868)
0.1 to 3.0 fiM. 8 wells were used for each concentration of TKI. Control cells were
incubated in experimental medium without additive. The cells were incubated at
37°C for 72 hours with changes o f experimental medium +/- TKI at 48 hours.
Every 24 hours incubation, one plate for each condition was treated by adding 50 |il
MTT dye ( concentration 5 mg/ml in sterilised PBS) and the MTT assay carried out 
as described in section 2.7.3. of the Methods chapter.
R e s u lts
The results of the TKI sensitivity studies are expressed in the form of time course 
and dose response for OAW42, PE O l, and PEO lcddp cells. These are shown as 
means of 3 independent experiments and the standard error o f the means are 
indicated by the error bars.
There was no significant inhibition of OAW42 cells over 24 hours fig. 30. After 48 
hours, significant inhibition was not observed until a dose of 1.0 |aM was matched.
reaching a maximum of 48.4% (p < 0.0001) below contiol cell growth at 3.0 
dose. A fter 72 hours exposure, cell proliferation was inhibited to 27.5% (p < 
0.0001), and 38.3% (p < 0.0001) below control cell growth at 1.0, and 3.0 jiM 
dose respectively.
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Figure 31 shows the effect of TKI on growth of PEO l ovarian cancer cell line. 
After 24 hours exposure, data showed a slight rise in cell proliferation of 19.7%
(p < 0.02) above control cell growth at 0.1 |iM  dose and inhibition to the cell
proliferation at 3.0 |iM  dose of 22.6% (p = 0.009). After 48 hours exposure, cell
proliferation was inhibited at all doses reaching a maximum of 40.3% (p < 0.0001)
at 3.0 |iM  dose. After 72 hours exposure similar results were seen as in 48 hours
exposure, reaching a maximum of 55.0% (p < 0.0001) below control cell growth. 
Figure 32 shows the effect of TKI on growth of PEOlcddp ovarian cancer cell line. 
After 24 hours exposure cell proliferation was inhibited by increasing concentration 
o f TKI reaching a maximum of 48.9% (p < 0.0001) below control cell growth at
3.0 |liM. Similar results were seen after 48 hours exposure, reaching a maximum of
46.4% below control cell growth. D ata after 72 hours exposure show highly 
decreased of cell proliferation at all TKI doses, reaching a maximum of 59.3% (p <
0.0001) below control cell growth at 3.0 |iM.
Conclusion
The effect o f TKI on OAW42 cells compared with PEO l and PEO lcddp cells. As 
can be seen from the results, the effect of TKI on growth of OAW42 cells shows 
inhibition to the growth over 48, and 72 hours reaching a maximum of 48.4% at
3.0 jiM dose.
P E O l cells shows growth inhibition after 24, 48, and 72 hours reaching a 
maximum of 55% at 3.0 fiM dose.
PEO lcddp cells shows growth inhibition after 24, 48, and 72 hours reaching a 
maximum of 59.3% at 3.0 dose.
This com parison illustrates that the three cell lines were growth inhibited by 
different doses of TKI, with the greatest effect seen in PEO lcddp cells. Hence, 
there is good support for the use o f this TKI in treating drug resistant ovarian 
cancer.
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F igure 30. Effect of TKI (ZM 252868) on the growth of OAW42 human ovarian 
cancer cell lines. Cells were grown in experimental medium (Phenol Red Free 
Medium) supplemented with 5% DHIDCCFCS and exposed for 24, 48 or 72 hours
to increasing concentrations o f TKI (0.1 to 3.0 |iM ). Values represent mean +/-
SEM (bars) of triplicate experiments. Control with out TKI.
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F igure  31. Effect of TKI (ZM 252868) on the growth o f PEO l human ovarian 
cancer cell line. Cells were grown in experimental medium (Phenol Red Free 
Medium) supplemented with 5% DHIDCCFCS and exposed for 24, 48 or 72 hours
to increasing concentrations of TKI (from 0.1 to 3.0 p.M). Values represent mean
+/- SEM (bars) of triplicate experiments. Control with out TKI.
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Figure 32. Effect of TKI (ZM 252868) on the growth o f PE O lcddp human 
ovarian cancer cell line. Cells were grown in experimental medium (Phenol Red 
Free Medium) supplemented with 5% DHIDCCFCS and exposed for 24, 48 or 72
hours to increasing concentrations of TKI (0.1 to 3.0 p.M). Values represent mean
+/- SEM (bars) of triplicate experiments. Control with out TKI.
Time course and dose response of PEOlcddp
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3.13 GROW TH RESPONSE TO A COMBINATION OF EGF+TKI
From the previous study it was concluded that TKI (ZM 25868) inhibited growth 
of all three cell lines. As the inhibitor is said to be specific for the EOF receptor, it 
was of interest to determine whether addition of a known inhibitory dose of TKI
(0.5 |J,M) could, overcome the stimulation by EOF.
Method
The three cell lines were subcultured as in section 2.4.3. of the Methods chapter. 
Cells were plated down using 3x96 well tissue culture plates per cell line as in 
section 2.7.2. of the Methods chapter. The cells were then allowed to plate down 
for 24 hours before the routine medium was removed and the cells washed twice 
with PBS. Experimental medium (Phenol Red-Free Medium) supplemented with 
5% DHIDCCFCS in the presence of increasing concentrations of EGF plus a fixed
level of TKI (ZM 252868, 0.5 pM ). Control cells were incubated in experimental
medium without additive. The cells were incubated at 37°C for up to 72 hours with
a change of experimental medium after 48 hours incubation. After every 24 hours
exposure, one plate o f each cell line was treated by adding 50 p i MTT dye
(concentration 5 mg/ml in sterilised PBS). The MTT assay was carried out as 
described in section 2.7.3 of the Methods chapter.
Results
The results of the effect o f EGF -t- TKI on growth o f ovarian cell lines are 
expressed in the form of time course and dose response. These are shown as the 
mean o f 3 independent experiments and the standard en o r o f the means are 
indicated by the error bars.
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Figure 33 shows the effect of different doses of EGF + TKI (0.5 pM) on growth
of OAW42 cells. After 24 hours incubation data shows stimulation to the growth 
reaching a maximum of 19.2% (p < 0.0001) at 2.5 ng/ml dose. After 48 hours 
incubation data shows slight increase in cell proliferation was observed reaching a 
maximum of 8.4% (p ~ 0.003) at 5 ng/ml dose, inhibition to the growth was seen 
in the other doses reaching a maximum of 11.2% (p = 0.02) below control cell 
growth at 50 ng/ml dose. After 72 hours exposure cell proliferation was inhibited 
by the effect o f EGF + TKI reaching a maximum of 20.3% (p = 0.0001) at 50 
ng/ml dose.
Figure 34 shows the effect of different doses of EGF 4- TKI (0.5 pM ) on growth
of PE O l cells. A fter 24 hours exposure data shows inhibition to the growth 
reaching a maximum of 34% (p ~ 0.005) at 50 ng/ml dose. After 48 hours 
exposure data shows a small stimulation at doses up to 10 ng/ml and growth 
inhibition was seen at high dose reaching a maximum of 17.8% (p = 0.2) below 
control cell growth. A fter 72 hours incubation an increase in cell proliferation 
reaching a maximum of 28% (p = 0.008) above control cell growth at 2.5 ng/ml
dose. Figure 35 shows the effect o f different doses of EGF + TKI (0.5 pM ) on
growth of PEO lcddp cells. After 24 hours exposure data showed inhibition to the 
growth reaching a maximum of 31% (p = 0.007) below control at 50 ng/ml dose. 
After 48 and 72 hours exposure data showed inhibition to the growth reaching a 
maximum of 19 and 23% (p = 0.4) below control cell growth at 50 ng/ml dose 
respectively.
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C o n c lu s io n
The effect of EGF + TKI on growth of three cell lines OAW 42, P E O l, and 
PEO lcddp cells compared with effect of EGF alone. As can seen from figure 33 the
effect o f different doses of EGF + TKI (0.5 pM) on growth of OAW42 cells. After
24 hours incubation there was slight increase in cell stimulation was observed 
compared to the different doses o f EGF alone (figure 11). After 48 and 72 hours a 
slight decrease in the cell growth was observed compared to the effect of different 
doses of EGF alone.
Figure 34 shows the effect of different doses o f EGF + TKI (0.5 pM ) on growth
of PE O l cells. After 24 hours incubation a decrease in cell proliferation was seen 
compared to the EGF alone. After 48 and 72 hours there was an increase in cell 
proliferation compared to the effect of the same doses o f EGF alone (figure 12).
Figure 35 shows the effect of different doses of EGF + TKI (0.5 pM ) on growth of
PEO lcddp cells. There was no effect seen in cell proliferation after 24,48, and 72 
hours incubation compared to the effect of the same doses of EGF alone (figure 13) 
This comparison illustrates that more inhibition to the tyrosine kinase of EGFr in 
OAW42 and PEO l cells than PEOlcddp cell line due to the effect of TKI dose.
I l l
Figure 33. Effect of EGF + TKI (ZM 252868) on the growth of OAW42 human 
ovarian cancer cell line. Cells were grown in experimental medium (Phenol Red 
Free Medium) supplemented with 5% DHIDCCFCS and exposed for 24, 48 or 72
hours to increasing concentrations of EGF (From 2.5 to 50 ng/ml) + TKI ( 0.5 pM)
Values represent mean +/- SEM (bars) of triplicate experiments.
Time course and dose response of OAW42
cells to EGF + TKI
Ec
in
scraXIo<nXI<
2 . 5  5 1 0 2 0  5 0
EG F  ( ng /m l )  + ZM 2 5 2 8 6 8  (0.5 | iM )
□  24 h  
a  4 8 h
□  72h
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F ig u re  34. Effect o f EGF + TKI (ZM 252868) on the growth o f PE O l human 
ovarian cancer cell line. Cells were grown in experimental medium (Phenol Red 
Free Medium) supplemented with 5% DHIDCCFCS and exposed for 24, 48 or 72
hours to increasing concentrations o f EGF (2.5 to 50 ng/ml) + TKI (0.5 pM).
Values represent mean +/- SEM (bars) of triplicate experiments.
Time course and dose response of PE01
cells to EGF + TKI
Ec
o
m
nc(0JQO(0JO<0
EG F  ( ng /m l )  ^  ZM 2 5 2 8 6 8  (O.S^M ) 
a  24 h 
in  48 h 
□  72 h
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F ig u re  35. Effect of EGF + TKI (ZM 252868) on the growth of PEO lcddp 
human ovarian cancer cell line. Cells were grown in experimental medium (Phenol 
Red Free Medium) supplemented with 5% DHIDCCFCS and exposed for 24, 48 or
72 hours to increasing concentrations of EGF (2.5 to 50 ng/ml) + TKI (0.5 pM).
Values represent mean +/- SEM (bars) of triplicate experiments.
Time course and dose  response  of PEOlcddp
cells to EGF+TKI
0 . 8-
Ec
o 0 .6-
ouc(0S i 0.4-o
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<
0 .2-3E
0.0 50201 052.5C
EGF (ng/ml) + ZM 252868 (O.S^M )
□  24h 
^  48h
□  72h
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3.14 M O RPHO LO GICA L CHANGE OF OAW42
Study of the changes of morphology of OAW42 ovarian cancer ceils, in response 
to the effects o f LH and EGF, in comparison to control, was carried out by 
electron microscopy.
M eth o d
Exponentially growing cells were harvested by trypsinization and plated down in 
4x25 cm^ tissue culture flasks at densities of approximately 5x10^ cells per flask, in 
RPMI 1640 containing 10% PCS. After 24 hours incubation, to allow the cells to 
attach, the medium was removed and cells washed twice with PBS. Experimental 
medium (Phenol Red Free Medium) supplemented with 5% DHIDCCFCS in the 
presence of LH concentration (40 iu/1) and/or EGF concentration (10 ng/ml) was 
then added. Control cells were incubated in experimental medium without additive. 
The cells were incubated at 37°C for 72 hours with a change o f experimental 
medium at 48 hours. Experimental medium was removed, cells were washed with 
PBS and fixed in glutaraldehyde (see 2.10) and examined by electron microscopy.
Results
The comparison has suggested a number of interesting similarities and differences 
(changes in size o f mitochondria, changes in secretory activity) between cells 
treated for 72 hours with either LH or EGF. Figure 36 shows the transmission 
electron photomicrograph of OAW42 cells after exposure to EGF at 10 ng/ml up to 
72 hours. Polysomes are more easily observed than in control cells; mitochondria 
are more swollen (and there is trend for a greater number in the EGF-treated cells); 
more stubby microvilli can be observed. In contrast, after 72 hours exposure to 
LH, there is no apparent swelling of the mitochondria, the cytoplasmic polysomes 
are less prominent than after exposure to EGF and the number of stubby microvilli 
was much reduced-being similar to that on control cells.
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Conclusions
The effect of EGF on OAW 42 cells was to cause mitochondrial swelling, very 
prominent polysomes and more stubby microvilli, all presumably reflecting the 
overall of growth response to the effect of EGF after 72 hours incubation. The 
effect o f LH after 72 hours exposure shows no evidence for swelling of 
mitochondria, nor of cytoplasm-prominent polysomes and few stubby microvilli are 
seen. These results perhaps reflect the early growth inhibition by LH that was seen 
(figure 17) at 40 iu/1.
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F ig u re  36. Electron microscopic examination for morphological change of 
OAW 42 cell. Cells as control (A), Cells + LH (B), Cells + EGF (C) and Cells + 
LH and EGF (D). (11,457 magnifications).
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3.15 T G F -p l W HOLE»CELL BINDING ASSAY
Radio receptor assay of T G F -p l receptor in the OAW42 ovarian tumour cell line
was carried out through incubation of cells with l^5%_TGF-pl in the presence or
absence of unlabelled 20 nM TG F-pl, following the procedure illustrated in section 
2.10. of the Methods chapter.
Results
Counting efficiency -  40%
Specific activity = 1080 Ci/m mol
Total binding = 20706 cpm/200 p.1 aliquots of lysate cells
Non-specific binding = 15017 cpm/200 p i aliquots of lysate cells
Specific binding = Total binding - Non-specific binding 
= 20706- 15017 
= 5689 cpm 
IBq = 1 disintegration/sec 
IC i =3.7x1010 Bq 
1 KBq = 27 nCi 
5689 cpm = 5689/60 cps x 2.5 Mev 
= 237 dps 
= 237 Bq
= 0.237x27 = 6.4 nCi 
1080 Ci/m mol
1.08x10^ Ci/m mol 
6.4 nCi 
6.4xlO-9Ci 
6.4xlO-9Ci
1.08xl03Ci/m m
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= 5.9xlO 'l^ m mol 
= 5.9xl0'15 mol
5.9 f mol/200 pi receptor binding buffer
29.5 f  mol/ml
29.5 f  mol receptor/mi
180 pg DNA/ml, (DNA was measured by using Hoechst DNA assay see (section 
2.5.2) of the Methods chapter.
46 pg  Protein/ml, (Protein was measured by using Bradford protein assay see 
(section 2.6.2) of the Methods chapter.
Receptor fmol/ml
DNA pg/ml
29.5/180 = 0.16 f  mol Receptor/pg DNA
= 6,000 sites/cell 
Receptor f  mol/ml
Protein pg/ml
29.5/46 = 0.64 f mol Receptor/pg Protein 
C o n c lu s io n
The presence of TGFp binding activity in OAW42 cells has been demonstrated. 
From the previous result of dose response of cells to TGFp, as seen from figure 
16, growth inhibition of OAW 42 cells occunod at all doses o f TGFp but the 
receptors appeared to be almost satiaated at 5 ng/ml..
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CHAPTER IV
D IS C U S S IO N
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D IS C U S S IO N
Ovarian cancer arises almost exclusively in epithelial cells derived from the 
surface of the ovary. It is thought that the combination of repeated damage 
caused by ovulation (break of the epithelial surface layer to allow release of 
the follicle) and subsequent repair is the prime factor in the promotion of 
any transformed cells into ovarian epithelial cancer. Thus, stimulation by the 
factors involved in this wound repair could be critical. The most obvious 
candidate is epidermal growth factor (EGF) as the principal factor in all 
epithelial wound repairs.
EGF works through the EGF receptor (EGFr) and EGFr has been detected 
in about 45% of human ovarian epithelial cancer (Owens, et al 1991). Little 
is known about the regulation of EGFr in ovarian epithelial cells. Malignant 
cells may escape normal growth regulatory controls by secreting growth 
factors into their local environment (Todaro, et at 1980).
Production of growth factors by some tumours of epithelial origin has been 
characterized as autocrine stimulation (Browder, et al 1989). These growth 
factors may be necessary for optimal in vivo growth of the tumours 
(Wilson, et al 1991).
Normal human ovarian epithelial cells express both EGF and epidermal 
growth factor receptors (Scuixy, et al 1994 ). However, EGF was detected in
only 27.6% of samples of ovarian cancer whereas T G F a  was present in
88.5% (Owens, et al 1991). Data have been presented in this thesis which 
demonstrate the importance of growth factors in determining proliferation of 
ovarian cancer cells and how growth regulation can be modulated on the one
hand by TGFp, and on the other hand by T G F a, EGF and a tyrosine
kinase inhibitor which selectively blocks the EGF receptor.
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The initial phase of this thesis described the control of cell proliferation 
using DNA and MTT assay methods based on the published method of 
Leake and Habib (1987) for DNA assay and Mossmann (1983) for MTT 
assay regarding to the effects of growth factors and hormones.
To establish whether ovarian cancer cell lines respond to exogenous peptide 
growth factors. OAW 42 epithelial ovarian cancer cells (gift from Dr. A. 
Wilson), previously established from the ascites o f a patient with ovarian 
cancer, were initially used. PEO l and the platinum resistant PEO lcddp (gift 
from Dr. S. P. Langdon) were selected to further the study because they represent 
ovarian cancer cell lines from a patient whose tumour was initially sensitive 
to platinum but then became resistant to platinum therapy.
Growth response to EGF shows that OAW42 cells respond positively to the 
influence of EGF after 48 and 72 hours reaching a maximum of 34% and 
21% above control at 10 ng/ml and 5 ng/ml respectively (as seen in figure 
11). PEO l cells showed earler stimulation to EGF, reaching a maximum of 
about 18.9% after 24 hours, 30.8% at 48 hours and 16.1% after 72 hours 
at the same dose of EGF (2.5 ng/ml) in contrast to the differences in
maximum dose for TG Fa.
The PEO l cell line has also been reported by others to be growth stimulated 
at concentrations between 0.1 and 10 nmol/1 (Crew gf a/ 1992). This report 
found maximum stimulation at 1 nmol/1, which compares with the 5 ng/ml 
seen in the experiments described here (1 nmoI/1 = 5.3ng/ml).
PEO lcddp cell growth responds to the direct influence of EGF. After 24 
hours exposure there was a slight stimulation by 5 ng/ml (about 6.3% above 
control). After 48 hours there was no significant stimulation of growth seen 
and EGF inhibited growth at all doses after 72 hours. The EGFr may all be 
saturated with the ligand after 48 hours and probably this may be the reason why no 
stimulation was observed after 72 hours.
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To investigate the balance of sensitivities to TG Fa in both cell lines OAW42
and PE O l, the time course and dose response curves were determined (figure
14 and 15). These show the growth response to T G F a  in OAW42 cells
gave a slight rise of cell proliferation at a dose of 10 ng/ml at 24 hours 
incubation, whereas PE O l showed a maximum of cell proliferation about 
35% above control at 25 ng/ml dose. After 48 hours both cell lines were
growth stimulated by effects o f T G F a  (10 and 50 ng/ml), reaching a
maximum of 9.3 and 41.3% above control respectively, data after 72 hours 
showed a maximum of cell growth of 24.4% at 10 ng/ml.
Thus, although both cell lines respond to T G F a, the dose required to
induce maximum response is significantly less in OAW42 than in PEO l but 
the extent o f stimulation of growth is much higher in P E O l. Compares with
Crew values for maximum response to T G F a  in between (0.1 and 10 nmol/1). 
In conclude OAW42 cells more sensitive to E2, PEO l more sensitive to GF’s.
TG F-p  is a peptide growth factor that has been shown to inhibit
proliferation of many normal and cancer epithelial cells. TG F-p inhibited
proliferation of normal ovarian epithelial cells between 40-70% (Berchuck et al
1991). These data suggest that TGF-p might act as an autocrine growth
inhibitor factor in normal ovarian epithelium. The OAW42 ovarian cancer
cells were also markedly growth inhibited by 96 hours exposure to TG F-pl
(about 33.5 and 35.9%) at 1.0 and 5.0 ng/ml, respectively (as seen in figure 
16 ).
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These results contrast with the evidence from Hurteau et al (1994) who 
found that immortalized ovarian cancer cell lines were resistant to the
growth inhibitory effect o f TG Fp and frequently had lost the ability to
produce or activate this growth factor.
In contrast, in their studies, TGF-p (10 ng/ml) significantly inhibited (3H)
thymidine incorporation in 19 of 20 (95%) primary ovarian cancers. This
would lend support to the idea that loss of inhibition by TGF-p is a critical
step in the progression of ovarian cancer but it may also simply illustrate 
the differences that can be found among different ovarian cancer cell lines.
TGF-p is synthesised and secreted by the thecal cells. Nevertheless, thecal
cells do not appear to have TGF-P receptors and the main target is thought 
to be the granulosa cells, though ovarian cancer cells in culture show 
mai'ked growth inhibition by TGF-P, leading to the concept that a balance of
control by TG F’s a  and p may regulate the progression of some ovarian
cancers (Huteau, etal 1994, Bast et al 1995). Increased activity of T G Fa
and decreased activity of TG Fp may contribute to the development of many
ovarian cancer. Loss of TGFP responsiveness has been associated with the
downregulation of c-myc expression in the development of ovarian cancer 
(Chow et al 1996).
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Conclusions from these studies are that OAW42 and PEO l ovarian cancer
cells express EOF receptors and are responsive to EOF and T G F a. This
supports the suggestion that the growth of certain ovarian cancers could be 
maintained by EGF through the EGF receptor (Owens et al 1991a). EGF 
receptor have been reported to be present in about 50% of ovarian tumours
extracts (Bauknecht et al 1989) and (Leake et al 1990), T G F a  has been
found in 88% of ovarian cancers (Owens e ta l  1991b).
Therefore EGF and T G F a may have a role in autocrine and/or paracrine
growth modulation o f ovarian cancer.
The results showed that T G pp inhibited cell proliferation and DNA synthesis
in OAW 42 cells. These results together with those from previous studies
show that these cells express TG Fp, T G F a and EGF receptors and that
overall cell growth may be modulated by a balance o f these growth factors 
in an autocrine and/or paracrine manner.
Another example of the link between hormones and growth factors was 
provided by the study o f Luteinizing hormone (LH) regulation of ovarian 
cancer cell growth. Growth response to LH, was studied at various 
concentrations. LH was shown to inhibit growth of both OAW42 and PEOl 
cells. As seen in figures (17) and (18), by increasing the dose of LH there 
was an increase in cell inhibition, reaching a maximum, in the two cell 
lines, o f about 21.3 and 55.5% respectively below control at 60 iu/1 dose 
after 24 hours exposure of each cell line to LH. After 48 and 72 hours 
OAW 42 cell growth exhibited a maximum inhibition reaching about 32% 
below control at 60 iu/1 at both 48 and 72 hours. PE O l showed greater 
inhibition (about 58.2 and 78.7% below control after 48 and 72 hours 
respectively)
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The previous study showed that LH is capable of causing dose dependent 
inhibition of ovarian cancer cells at least in vitro. In order to determine
whether LH increased the synthesis and secretion of active TGFp into the
cell culture medium, cells were co-incubated with both LH and commercially
available anti-TGFp polyclonal antibody at 5 and 30|j,l/ml. As is seen in figure
(18), this antibody reversed the growth inhibition by LH and even allowed
growth (11.3%) above control indicating that TG Fp partially suppresses
OAW42 cell growth under control conditions. These results suggest that the 
anti-proliferation effects of LH on ovarian cancer cells are mediated by
release of TGFp. Therefore it is appears that TGFp is a hormonally
regulated growth inhibitor with possible autocrine function in ovarian cancer 
cells.
Presence of EGF receptor, has been confirmed by demonstrating the binding 
of iodinated EGF to total particulate fractions of the cell lines. Scatchard 
analysis of the ligand binding data indicated that OAW42 and PEO l cells 
exhibited high affinity EGF receptor with a maximum binding capacity, 24.8 
and 21,5 fmol/mg protein, and dissociation constant (Kd), 0.833 and 0.840 
nM respectively as can seen in Table ( 3 ) .
Cancer and other hyperproliferative diseases are associated with elevated 
protein tyrosine kinase activity, related to the increased activity of growth 
factor receptors. It has been hypothesized that chemical blockers, particularly 
of the substrate domain of the receptor protein tyrosine kinase, might prove 
to be effective and potentially selective inhibitors of cellular proliferation in 
diseases which are regulated by a cell growth factors and hoimones 
(Arteaga, et al 1988, Osborne, et al 1976, and Arteaga, et al 1989).
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The first class of tyrosine kinase inhibitors described, called tyrphostins, had 
some selectivity for the EGF receptor (Yaish, et al 1988). Further more, 
these tyrphostins were more potent inhibitors of EGF-stim ulated cell 
proliferation than of serum- stimulated cell proliferation.
To confirm  that selective inhibitors can block EGF receptor 
autophosphorylation in ovarian cancer cells, the effects of Zeneca inhibitor 
ZM 252868 on the OAW 42 ovarian cancer EGF receptor positive cell lines 
were determined. After exposure of these cells to varying concentration of 
ZM 252868, EGF receptor tyrosine kinase enzyme activity demonstrated 
significant inhibition. Tyrosine phosphorylation of the EGF receptor was 
inhibited in a dose dependent manner (fig. 29), reaching a maximum of about
88% below control cell enzyme activity at the maximum dose (3 |iM) of ZM
inhibitor. This inhibition of TK activity was reflected in reduced growth, as 
shown in (figure 29) as the 88% inhibition of TK activity led to 60% 
growth inhibition after 72 hours.
It is possible that, in intact cells, the tyrosine kinase activity of other growth 
factor receptors or other tyrosine kinases critical to rapidly proliferation cells 
are also inhibited by this agent. Further studies are needed to show whether 
all the effects observed are mediated through the EGFr.
Other studies show that several tyrosine kinase inhibitors inhibit in vivo 
growth (Gillespie, e ta l 1993). Data from Fry, e ta l  (1994) shows that the 
PD 153035 inhibited the EGF receptor tyrosine kinase by 50% below 
control (not as effective as the ZM 252868). Our data do show that tyrosine 
kinase inhibitor can inhibit proliferation of ovarian cancer cells.
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Taking this into account, the present data raise the possibility that ZM 
252868 may prove to be useful new agent for the treatment of ovarian 
tumours. Other work from our laboratory (Leake cf al 1995) has shown that 
the EGF receptor TK activity is markedly elevated in PEO lcddp cells. If it 
can be confirmed that elevated EGFr TK activity is common in platinum 
resistant tumours, the use of inhibitor like ZM 252868 might be very 
promising for patients with drug resistant tumour. Other tumours may also be 
responsive to this a approach.
Election microscopy was used, to study the hormonally-induced changes in 
the cellular morphology which occur as ovarian cancer cells form three- 
dimensional structures. EGF was studied because it is thought to be the 
major factor involved in the wound repair after ovulation.
The comparison has suggested a number of interesting similarities and 
differences in terms of changes associated with differentiation (changes in size 
of mitochondria, changes in secretory activity). Exposure of OAW42 cells to 
EGF at 10 ng/ml dose up to 72 hours cause mitochondrial swelling, very 
prominent polysomes and more stubby microvilli. Exposure of cells to LH at 
40 iu/1 after 72 hours incubation shows no evidence for swelling of 
m itochondria, nor of cytoplasm -prom inent polysomes and few stubby 
microvilli are seen. These results reflect the growth promotion and inhibition 
which is induced in OAW42 cells by these two factors.
C o n c lu s io n s
The study concerning the potential role of growth factors and hormones in 
the growth regulation o f human ovarian cancer cells. Most ovarian cancers 
arise from single colonies of cells that have undergone multiple genetic 
alterations. Although most primary ovarian cancer cells remain sensitive to
the growth-inhibitory effect of transforming growth factor-beta (TGF-p), loss
of production may interrupt the transforming growth factor-beta autocrine
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inhibitory loop and play a role in the development of some ovarian cancer. 
The inhibitory effects exerted by both LH and TGF-p on the proliferation of 
OAW 42 cells clearly indicate these cells retain both their autocrine and 
paracrine growth inhibition by TGF-p.
Stim ulatory effects by both growth factors T G F a  and EGF on the
proliferation of OAW42 and PE O l ovarian cancer cells were demonstrated. 
Both cell lines OAW42 and PEO l were shown to be EGF receptor positive.
Therefore EGF and T G F a can be autocrine and/or paracrine growth factors 
in ovarian cancer.
Ovarian cancer arises from promotion of transformed epithelial cells by
T G Fa/E G F, acting at the sites of ovulatory damage. This promotion is
m ediated through the EGF receptor. Tyrosine kinase inhibitor inhibit
proliferation of epithelial ovarian cancer cells at dose over 1.0 |iM. Inhibition
of the EGFr-associated T.K. can block this growth stimulation. As platinum 
resistant cells have elevated EGFr-TK, this may be a route for therapy for 
patient-resistant tumours. LH inhibits ovarian cancer cell growth through
modulation o f TGF-P function. As ovarian cancer progresses a loss of
inhibition by TGF-p may be intical step in tumour progression. These
hormonal and growth factor effects are reflected in changes induced in 
cellular morphology of mitochondria, microvilli and polysomes.
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